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Abstract
Research spanning over a few decades has contributed to the 
discovery and understanding of a population of cells that are precursors of 
connective tissue cell-types. These cells currently referred as Mesenchymal 
Stem Cells (MSCs), have also been shown by some researchers to have the 
capacity to give rise to neuron- and muscle-like cells in vitro, making them 
very attractive as cellular source for clinical application in regenerative 
medicine. Despite the intense focus on therapeutic research on going in the 
MSC field, the biology of these cells remains elusive, especially at its 
hierarchical organisation. Although some data suggest that MSCs are 
composed of different sub-populations of progenitors or cells that are 
prompted to differentiate preferentially into one or few different cell-types in 
vitro, there is no defined hierarchy proposed yet, especially at the most 
primitive level.
The initial aim of this project was to characterise the adult murine 
MSC (muMSCs) compartment since most of the studies performed to date 
were conducted with human cells. During the process of such, a new cell 
type was found. Under a conventional isolation/culture system a minor sub­
population of muMSCs was identified and then characterised (based on the 
expression of SSEA-1 antigen; Stage Specific Embryonic Antigen-1). The 
data presented strongly suggest that this new sub-population is not only the 
founder of the MSC compartment but also they are multipotent both in vitro 
and in vivo. Moreover, this new cell-type can be directly identified from fresh 
bone marrow thus confirming its true existence in vivo. Detailed study on 
SSEA-1 pos-MSCs revealed that these cells present several common features 
with Embryonic Stem Cells (ES) and therefore suggests that a group of cells 
with embryonic features might persist throughout adult life.
The identification/characterisation of these adult murine SSEA-1pos 
cells should facilitate the identification of a similar cell-type in the human 
MSC compartment. Furthermore, this study opens new questions on the 
developmental origin and importance of adult tissue-specific stem cells in the 
maintenance of tissue homeostasis.
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Chapter 1 - General and Concise Introduction
The bone marrow mesenchymal compartment contains 
stem/progenitors of skeletal tissue components such as bone, cartilage, the 
haematopoiesis-supporting stroma and adipocytes. These cells are currently 
denominated by mesenchymal stem or progenitor cells (MPCs). In addition, 
they may be experimentally induced to undergo unconventional 
differentiation, possibly forming neural-, myogenic-, endothelial- and visceral 
mesoderm-like cells. As such, they represent an important concept of post­
natal non-haematopoietic stem cells and an easy source for potential 
therapeutic use. Despite having been studied for more than three decades 
and currently being used in different clinical settings, their biology remains 
elusive. Based on the aim of this project, the main focus of this introductory 
chapter will be an overview of the basic in vitro and in vivo biology of these 
cells, followed by a more detailed discussion on the hierarchical organisation 
of the bone marrow mesenchymal compartment. As such, other areas in 
which MSCs were used as vehicles for gene therapy, models to study the 
molecular mechanisms of adipogenesis, osteogenesis, or other 
differentiation pathways and also characterisation of their immunomodulatory 
properties will not be discussed here.
1.1 - What is a mesenchymal stem cell?
The adult bone marrow has generally been seen as an organ 
composed of two main and distinct lineages: the haematopoietic tissue and a 
group of mesenchymal-derived cells. Within this last group exists a putative 
subset of cells referred to as mesenchymal stem or mesenchymal progenitor 
cells. These cells can be ex vivo expanded and induced in vitro to 
differentiate into osteoblasts, chondrocytes, adipocytes, tenocytes, 
myoblasts, astrocyte/neuronal-like cells and haematopoietic-supporting 
stroma (Dennis etal., 1998; Dexter, 1982; Majumdar etai., 1998; Pittenger et 
a i, 1999). The multipotentiality of these cells, their relatively easy isolation
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and culture (especially from humans), as well as their high ex vivo expansion 
potential, renders these cells an attractive therapeutic tool.
Despite increasing experimental and clinical interest in recent years, 
the understanding of MSC biology remains elusive. In its most basic 
definition, a stem cell has the capacity for self-renewal and the ability to give 
rise to one or more types of differentiated progeny (Morisson et al., 1997; 
Prockop, 1999). Within that context, and based on its in vitro behaviour, it 
would seem that the MSC should be considered as a stem cell. It has been 
demonstrated that low-density plated MSCs can proliferate in vitro and 
expand more than a few hundred to a thousand-fold in a short period of time 
(Colter et al., 2000; Digirolamo et al., 1999; Javazon et a/., 2001) and they 
are able to give rise to different cell-types as mentioned above. However, 
characteristics of MSCs differ among species and according to the methods 
of isolation/expansion applied, and there is no specific marker or combination 
of markers that identify MSCs either in vivo or in vitro. Therefore, MSCs are 
currently defined by a combination of morphologic, phenotypic, and 
functional properties, many of which could be the result of in vitro 
manipulation.
Despite the terminology commonly used, whether MSC qualify as 
stem cell remains a valid question. MSCs have clearly not been proven to be 
stem cells (Jordan et al., 1990; Morisson et al., 1994, 1995 and 1997). 
Firstly, MSCs have not been demonstrated in vivo to be capable of 
regeneration or maintenance of a tissue compartment at a single cell level. 
Secondly, MSCs have not been transplanted, isolated, and serially 
transplanted. Because of the inability to prospectively isolate MSCs and to 
characterise them and study their biologic properties in a relatively 
unmanipulated state, the concept of an MSC remains an assumption based 
on extrapolations from in vitro studies.
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1.2 - Nomenclature used to refer to MSC or MPC
The first contribution to the understanding of mesenchymal precursor 
cells was made by Friedenstein and colleagues (Friedenstein et al., 1969 
and 1970). With the objective to identify cells in bone marrow responsible for 
bone formations in ectopic transplant studies, Friedenstein et al. 
demonstrated the growth of single cell-derived colonies of cells 
morphologically resembling fibroblasts (Friedenstein et al., 1969 and 1970). 
The clonogenic mesenchymal precursor cells responsible for colony growth 
under these conditions were originally termed as fibroblast colony-forming 
cells (CFU-F). This original term has been gradually abandoned and 
replaced by diverse names like marrow stromal cells (MsCs) (Prockop, 
1997), MSCs (Caplan, 1994) or MPCs (Conget and Minguell, 1999). As 
mentioned above, such denominations reflect a semantic rather than a 
functional issue, which applies not only to the putative stem cell perse, but to 
a vast repertoire of committed progenitors exhibiting at least one or more 
differentiation potentials in vitro.
CFU-Fs were described as rapidly adherent, non-phagocytic 
clonogenic cells capable of extended proliferation in vitro. However, in vivo 
CFU-Fs are essentially in a non-cycling state as demonstrated by 3H- 
thymidine labelling studies (Epichina and Latzinik, 1976; Keiliss et al., 1971). 
CFU-Fs have been detected in the bone marrow of essentially all species 
examined including cats, dogs, sheep, rabbits, non-human primates, and 
humans. The CFU-Fs plating efficiency is highly dependent on the culture 
conditions, and there is an immense variability in the requirements from one 
species to another. In rodents, irradiated marrow feeder cells are essential in 
addition to selected lots of serum, in order to obtain the maximum number of 
CFU-Fs, whereas in humans they are feeder cell-independent (Kuznetsov et 
al., 1997a). The mitogenic factors that are required to stimulate the 
proliferation of CFU-F are not completely known at this present time, but at 
least includes platelet-derived growth factor (PDGF), epidermal growth factor 
(EGF), basic fibroblast growth factor (bFGF), transforming growth factor-fl
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(TGF-li), and insulin-like growth factor-1 (IGF-1) (Gronthos et al., 1995; 
Kuznetsov etal., 1997b).
It is necessary to mention that the nomenclature of marrow stromal 
cells has also been utilised to designate haematopoietic-sustaining 
monolayers of long-term marrow stroma or Dexter-type cultures (Dexter, 
1982; Gartner et al., 1980). However, culture conditions, evolving 
phenotypes, differentiation potential and secretion products of the above 
cells are not similar and, in fact, are quite distinct to that of MPCs or 
mesenchymal stem cells (Chichester et al., 1993; Majumdar et al., 1998).
Indeed, the adherent layer derived from long-term in vitro bone 
marrow culture consists of fibroblastic cells, macrophages, adipocytes, 
endothelial cells, and smooth muscle cells (Dexter, 1982). The term of MSC 
used in this study refers to mesenchymal stem cells rather than 
mesenchymal stromal cells. Additionally, most of the understanding of MSC 
biology has been performed in humans, thus the majority of the examples 
referred to here were from studies performed on human cells, especially 
bone marrow derived MSCs (hMSCs).
1.3 - In vitro characteristics of MSCs/MPCs
1.3.1 - General in vitro features of MSCs/MPCs
MSCs can be isolated from different sources, which include adult bone 
marrow (BM), peripheral blood, adipose tissue, cord blood and different 
foetal tissues (Campagnoli et al., 2001; Charbord et al., 2002; Gronthos et 
al., 2001; Kuznetsov et al., 2001; Zuk et al., 2002). Most MSC populations 
have been isolated via methodology originally described by Friedenstein and 
later modified by Caplan utilising the physical property of plastic adherence 
(Friedenstein et al., 1992; Haynesworth et al., 1996). However, 
macrophages, endothelial cells, lymphocytes, and smooth muscle cells also 
adhere to plastic and contaminate early BM preparations, especially from 
mouse BM preparations (Clark etal., 1995; Deans and Moseley, 2000).
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Enrichment for MSCs can be achieved by expansion and passing in relatively 
low-serum containing medium, ultimately eliminating contamination (Colter et 
al., 2001; Digirolamo etal., 1999; Javazon etal., 2001). In mouse-derived 
cultures, the resulting adherent fractions remain morphologically 
heterogeneous, containing cells ranging from narrow spindle shaped to large 
polygonal and, in some confluent cultures, tightly packed, slightly cuboidal 
cells. Although in human-derived adherent fractions, the cultures display a 
rather homogeneous “look” of fibroblast-like cells, cell cycle studies revealed 
that they are rather heterogeneous. In fact, while a small fraction of 
MSC/MPC are actively engaged in proliferation, the vast majority of cells are 
standing at the G0/G1 phase of the cell cycle (Conget and Minguell, 1999). 
Moreover, the G0/G1 population of MSC includes a minor and variable 
subset of resting quiescent cells, as evidenced by RNA and DNA content 
(Conget and Minguell, 1999).
After subcultivation, hMSC have highly variable expansive potential. In 
some cases, some preparations can be expanded over more than 15 cell 
doublings, others cease replicating after just a few cell doublings (Bruden et 
al., 1997; Digirolamo etal., 1999; Phinney et al., 1999a) This may arise from 
several factors, amongst them the procedure used to harvest the marrow 
(Bruden etal., 1997; Blazsek et al., 1999; Digirolamo et al., 1999; Phinney et 
al., 1999a), the low frequency of MSCs in marrow harvests (Koc et al., 1999), 
and the age or condition of the donor from which MSCs were originated 
(D’lppolito et al., 1999; Galotto et al., 1999; Phinney et al., 1999b). In 
moderate subcultivation situations, MSCs maintain their normal karyotype 
and telomerase activity (Pittenger et al., 1999). However, extensive 
subcultivation impairs cell function by the onset of evident signs of 
senescence (Digirolamo et al., 1999; Rubio et al., 2005) and/or apoptosis 
(Conget and Minguell, 1999).
16
1.3.2 - Immunophenotype and production of cytokines/matrix molecules
Panels of surface antigens have been reported to be expressed on 
MSC derived from different cellular sources (Barry et al., 2001; Bianco et al., 
2001; Deans and Moseley, 2000; Deschaseaux et al., 2003; Filshie et al., 
1998; Gronthos et al., 1995; Lodie et al., 2002) although there is no 
agreement on the phenotypical characterisation in the published literature. 
Variation in the isolation techniques and culture media used to grow MSCs 
has led to variable findings regarding the phenotype of these cells in different 
laboratories. Nevertheless, MSCs display a repertoire of expression of 
different surface antigens, which includes numerous receptors important for 
cell adhesion with haematopoietic cells. Some of the surface antigens 
reported to be on human bone marrow derived MSCs are Stro-1 (Gronthos et 
al., 1999), CD13, CD71 (transferring receptor), CD73, CD90 (Thy-1), CD105 
(endoglin), CD106 (VCAM-1) and CD166 (ALCAM). In the murine system, 
these cells express Sca-1 and not CD90 (Peister et al., 2003). In general, 
however, MSCs uniformly lack antigens such as CD14 and CD45 that 
typically identify haematopoietic cells.
It is important to mention the expression of different types of a- 
integrins and hyaluronic acid on MSCs. This implies a dynamic participation 
of these cells in the marrow microenvironment, especially in the organisation 
of the extracellular matrix in the marrow or in the bone. This is further 
strengthened by data showing they produce a vast array of matrix molecules, 
including fibronectin, laminin, collagen, and proteoglycans (Chichester et al., 
1993, Pittenger et al., 1999; Prockop, 1997). Indeed, in vitro cell adhesion 
studies using different human CD34pos haematopoietic cell lines showed that 
adherence of these cells to stroma could be partially inhibited by divalent 
cation chelation or RGD peptide competition, implicating integrin-dependent 
adhesion (Ghaffari et al., 1997). Additionally, the attachment was sensitive to 
digestion by chondroitinase ABC, suggesting CD44-dependent binding 
interactions (Ghaffari etal., 1997).
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MSCs have been shown to constitutively secrete several cytokines 
(Cheng et al., 2000; Dormady et al., 2001; Haynesworth et al., 1996; 
Mbalaviele etal., 1999; Majumdar et al., 1998). Many of them are relevant in 
HSC (haematopoietic stem cell) proliferation and differentiation such as: IL-6 
(interleukin-6), Flt-3 ligand, SCF (stem cell factor), G-CSF (granulocyte- 
colony stimulating factor). MSC can support human LTC-IC (long-term 
culture-initiating cells), so they can provide a feeder layer for cultured HSC 
(Cheng et al., 2000; Kadereit et al., 2002), without additional cytokines. 
Moreover, MSCs can enhance hHSC engraftment in xenotransplant 
experiments when co-injected with haematopoietic cells (Angelopoulo et al., 
2003; Noort et al., 2002). The therapeutic potential of hMSCs supporting 
HSC engraftment in patients undergoing bone marrow transplantation has 
been studied in several settings. As an example, patients in remission 
following treatment for breast cancer showed rapid haematopoietic recovery 
after being infused with autologous cultured/expanded MSCs (Koc et al., 
2000).
MSCs also secrete cytokines with immunomodulatory effects such as 
IL-1, IL-11, IL12, (interleukin-1, -11, -12). Most of these and other 
immunomodulatory cytokines are produced by MSC in response to IL-1 
(Dormady et al., 2001; Haynesworth et al., 1996; Mbalaviele et al., 1999; 
Majumdar et al., 1998). The immune phenotype of cultured hMSCs is widely 
described as MHC-lpos, MHC-llne9, CD40neg, CD80neg and CD86neg (Tse etal.,
2003). It has been shown that treatment with interferon can up-regulate 
MHC-I and induce MCH-II expressions, but it does not change the co­
stimulatory molecule expression (Tse et al., 2003). This non-immunogenic 
status of MSCs suggests that these cells might be effective in inducing 
tolerance. For example, hMSCs have been shown to inhibit T-cell responses 
not only by direct contact but also by IL-10 secretion in a dose-dependent 
manner (Aggarwal and Pittenger 2005; Beyth et al., 2005).
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1.4 - In vitro differentiation capacities of MSCs
Being mesenchymal in origin, it is not surprising that MSCs can 
terminally differentiate into several mesenchymal cell-types upon appropriate 
stimuli in vitro. These differentiation assays have been commonly used to 
determine the multipotentiality of MSCs. However, in recent years several 
groups have reported that MSCs can also adopt the cell fates of 
neuroectoderm and endoderm origin (Black and Woodbury, 2001; Deng et 
al., 2001; Jiang et al., 2003; Kohyama et al., 2001; Lee et al., 2004; 
Sanchez-Ramos et. al., 2000).
After more than two decades, the original formulations of 
cytokines/chemicals used for differentiating MSCs in vitro have evolved and 
might differ from one laboratory to another. Nevertheless, some of the basic 
compounds used for each lineage specification will be concisely discussed 
here.
The osteogenic lineage differentiation is normally achieved by 
treatment with dexamethasone (dex), p-glycerolphosphate and ascorbate 
(Bruder et al., 1997). The responsiveness of the cells to such chemicals is 
measured by the increase in calcium mineralization of the extracellular matrix 
and in alkaline phosphatase (AP) activity. Usually, after 1 week, calcium 
accumulation is observed and AP activity is seen. Also the addition of other 
factors other than glucocorticoids, such as bone morphogenetic proteins 
(BMPs), increases the number of bone nodules in cell cultures (Gori et al.,
1999). The exact sequence of differentiation events is still not very clear; 
however, alkaline phosphatase increases then decreases when 
mineralization is well progressed, with osteopontin expression appearing 
prior to certain other matrix proteins, including BSPII (Bone Sialoprotein II) 
and osteocalcin. BSPII is first detected in differentiated osteoblasts forming 
bone and osteocalcin appearing with mineralization (Aubin, 1998; Liu et al. 
2003; Owen etal. 1991).
Adipogenic differentiation can be induced with a combination of 
different glucocorticoid family members, like 1-methyl-3-isobutylxanthine 
(IBMX), dex, indomethacin and insulin (Nakamura et al., 2003; Ryden et al.,
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2003; Pittenger et al., 1999). Induced cultures will accumulate lipid vacuoles 
as well as the lipogenic enzymes glycerol-3-phosphatase dehydrogenase, 
lipoprotein lipase and fatty acid binding protein (aP2). Cells containing lipid 
vacuoles are observed following staining with Oil Red O solution after 2-3 
weeks of induction. These adipocytes usually remain healthy in culture for a 
few months. In general, MSCs can be differentiated into the adipocyte 
lineage in a similar fashion as pre-adipocyte cell-lines, such as 3T3-L1 and 
3T3-F442A, when stimulated with these adipogenic hormones (Nakamura et 
al., 2003; Ryden et al., 2003). However, phenotypic changes, such as lipid 
vesicles, can be observed at a later stage in comparison to the already pre­
committed cell-lines (Nakamura et al., 2003; Ryden et al., 2003). 
Nevertheless, similar key regulatory genes are necessary and sufficient for 
this conversion, which involves the CCAAT/ enhancer binding proteins 
(C/EBPs) a, p, 6, as well as the peroxisome proliferators-activated receptor 
(PPARy; Nakamura etal., 2003; Ryden etal., 2003; Suzawa etal., 2003).
Chondrogenic differentiation is observed when cells are exposed to 
the influence of TGF-p3 (Mackay et al., 1997). Cultured MSCs are placed in 
suspension in a polypropylene tube and gently spun in a centrifuge to form a 
pelleted micromass that develops in a multilayered matrix. After culturing in 
serum-free medium for 2-3 weeks containing TGF-p3, the cells express an 
extensive matrix rich in cartilaginous proteoglycans. These chondrocytes 
express type-ll collagen and chondrocyte-like lacunae can be observed in 
histological sections (Mackay et al., 1997).
Wakitani et al. demonstrated that MSC can also differentiate into 
myoblasts and myotubes by treatment with 5’-azacytidine. Although the exact 
mechanisms by which 5’-azacytidine induces myogenic differentiation on 
MSCs are not known, it has been suggested that this cytosine analogue may 
activate some silent genes by inhibiting DNA methylation (Chiu and Blau, 
1985; Creusot et al., 1982; Jones and Taylor, 1980) or induce changes in 
some specific genes to trigger their response to exogenous regulators 
(Clough et al., 1982). Indeed, myogenic differentiation was achieved when
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MSC cultures were also treated with horse serum (HS) and hydrocortisone, 
followed by 5’-azacytidine treatment (Gang et al., 2004; Reyes et al., 2001). 
Induced MSCs will gradually form myotubes and acquire expression of 
different myogenic proteins such as: desmin, myogenin, a-actinin, etc (Gang 
et al., 2004; Muguruma et al., 2003; Reyes et al., 2001; Santa-Maria et al., 
2004). New methodologies for myogenic differentiation are available 
nowadays, which includes induction with IGF-1 and co-culture with myocytes 
(Lee et al., 2005; Reyes et al., 2001; Santa-Maria et al., 2004).
Surprisingly, MSC seem to be able to differentiate into different tissues 
of embryonic neuroectodermal origin. Several reports have suggested that 
different agents, especially cytokines, growth factors, neurotrophins and 
retinoic acid (RA), could promote neural cell induction from MSCs in vitro 
(Black and Woodbury, 2001; Deng et al., 2001; Kohyama et al., 2001; Jiang 
etal., 2002 and 2003; Sanchez-Ramos et. al., 2000; Woodbury et al., 2000 
and 2002).
One of the methodologies applied by many groups implies that both 
rodent and human MSCs could be rapidly (minutes to a few hours) induced 
to differentiate exclusively into more than 70% of neurons in vitro by using 
simple chemical means (Black and Woodbury, 2001: Woodbury et al., 2000 
and 2002). The majority of induced MSCs not only exhibited a neuronal 
morphology, but also expressed several neuronal markers. Treatment with p- 
mercaptoethanol in serum-free medium induced changes in cell morphology 
as early as 60 min, formation of neuronal perikary and processes within 
hours and expression of the neuronal marker neuron-specific enolase (NSE; 
Black and Woodbury, 2001: Woodbury et al., 2000 and 2002). Similar results 
were observed with dimethylsulfoxide (DMSO) in combination with butylated 
hydroxyanisole (BHA) or butylated hydroxytoluene (BHT). Differentiated 
MSCs appeared to express the neuronal markers NSE, neurofilament-M, tau, 
and NeuN (Black and Woodbury, 2001: Woodbury et al., 2000 and 2002). 
However, these findings turned out to be artifactual as demonstrated by a 
recent study performed by Tuszynski’s group. Findings of this study indicated 
that chemical neuronal induction was a result of cellular stress leading to the
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physical contraction of cells into a neuronlike morphology. In addition, similar 
morphological changes can also be observed in other primary and 
transformed cell lines and by other deleterious chemical agents (Lu et al., 
2004). These results suggest that “neuronal induction” of MSCs by simple 
chemical means does not constitute a differentiation process but rather is a 
cellular response to environmental stress.
However, neuroectodermal differentiation can be achieved by 
stimulation with bFGF and EGF. This simple cytokine cocktail usually 
promotes towards a more astroglia phenotype (Jiang et al., 2002 and 2003; 
personal observations). However, some Tau and NeuN positive cells can 
also be obtained using such induction methodology (Jiang et al., 2002 and 
2003; personal observations). For a more appropriate neuronal differentiation 
several groups reported the use of this simple cytokine combination with 
additional factors such as, neuronal growth factor (NGF), RA, and others 
(Jiang et al., 2003; Kohyama et al., 2001; Sanchez-Ramos et al., 1998 and
2000)
In one study the authors used a demethylating agent, as well as the 
neural inducer Noggin, along with neurotrophins, to induce neural cell 
differentiation from rodent MSCs (Kohyama et al., 2001). Furthermore, small 
molecules such as dibutyryl cyclic AMP and IMBX that increase intracellular 
cyclic AMP, have been used for the in vitro differentiation of MSCs into 
neural cells (Deng et al., 2001). After induction, it usually takes several days 
or even weeks for MSCs to differentiate into neural cells, which is similar to 
the time needed for the neuronal differentiation of embryonic and neural stem 
cells (Kohyama et al., 2001; Jiang et al., 2002 and 2003 Sanchez-Ramos et. 
al., 2000). Furthermore, only a small proportion of pluripotent stem cells 
within the adult mesenchymal stem cell pool can be induced to differentiate 
into neurons with appropriate morphological and electrophysiological 
characteristics (Jiang etal., 2003; Kohyama etal., 2001).
More recently, some reports have shown that MSCs can also be 
induced to adopt the cell fates of visceral endoderm (hepatocyte-like cells) 
and endothelial-like cells In vitro (Cao et al., 2005; Lee et al., 2004; Reyes et 
al., 2001 and 2002). When hMSCs were stimulated with hepatocyte growth
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factor (HGF) and fibroblast growth factor-4 (FGF-4) for more than 3 weeks, 
cells started to acquire hepatocyte-like features with expression of specific 
markers like albumin and cytokeratin-18 (CK18) and adopt some functional 
features like albumin and urea production (Lee et a/., 2004). Simply treating 
with vascular endothelial growth factor (VEGF) induced MSCs to undergo an 
endothelial differentiation pathway (Cao et a/., 2005; Reyes et a!., 2001 and 
2002). A few studies reported that induced cells could acquire endothelial cell 
features by expressing the von Willebrand factor (vWF) and CD31 and could 
form “vascular tubes” in the angiogenesis assay in vitro (Cao et al., 2005; 
Reyes et al., 2001 and 2002).
1.5 - In vivo capacities of MSCs
In comparison to in vitro characterisation, there has been minimal data 
on the in vivo behaviour of MSCs. The data currently available can be 
separated into observations following site-directed, mostly via injury models, 
or systemic administration. Few studies have assessed the efficacy of the in 
vivo contribution of MSCs into different tissue cell-types or have examined 
whether donor cells engraft and differentiate into participatory cells or if the 
presence of donor cells is due to fusion events. Even less defined are the 
events after systemic administration. It seems that after systemic infusion, 
large numbers of the cells lodge in the pulmonary vascular bed and 
engraftment in other tissues (if at all) occurs with low frequency. Most of the 
studies used polymerase chain reaction (PCR) to access the presence of 
donor cells in different recipient’s tissues (Devine et al., 2001 and 2003; 
Liechty et al., 2000; Mahmud et al., 2004). Such sensitive methodology can 
detect the persistence of small numbers of cells and thus, could overestimate 
immensely the levels of engraftment (if it could be considered as such) of 
MSCs in vivo. In reality, the evidence supports non-specific lodging of MSCs 
in multiple vascular beds with persistence of very small numbers of donor 
cells in various tissues.
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1.5.1 - MSCs into bone and cartilage
The most successful in vivo application of MSCs has been for the 
repair of bone or cartilage. Evidence that MSCs are able to engraft in skeletal 
tissues came from early transplantation studies using gene-tagged 
(osteonectin and collagen-1 A1 genes) bone marrow cultures (containing 
MSCs) with demonstration of donor-derived osteoblasts/osteocytes in 
different areas of bone tissue (Hou et al., 1999; Pereira et al., 1998). These 
studies opened up the possibility to use MSC for treatment of genetic bone 
disorders, such as osteogenesis imperfecta (Ol; a disorder in which 
osteoblasts produce defective type-l collagen, leading to osteopenia, multiple 
fractures and severe bone deformities). Indeed, allogeneic MSCs were used 
to treat children with Ol. In these studies, patients that were infused with 
MSCs showed osteoblast engraftment (although at low frequency) and new 
dense bone formation (Horwitz et al., 1999 and 2002). Most patients had 
increased total bone mineral content in association with increased in growth 
velocity and reduced frequencies of bone fractures (Horwitz et al., 1999 and
2002).
Such experiments are useful to show the potential of unaltered MSC. 
Other approaches are available where MSC were transduced with a virus 
vector carrying a gene, which may influence the lineage restriction of the 
cells or correct a specific genetic defect. In a recent study, Chamberlain et al. 
showed that a gene construct targeting exon 1 of the gene for collagen-IA1 
can efficiently correct mutated collagen-IA1 production in MSCs 
(Chamberlain et al., 2004). The results obtained with these genetically 
corrected MSCs from two patients with osteogenesis imperfecta were 
extremely encouraging. In all cultures, genetically corrected MSCs were able 
to produce an adequate amount of wild-type collagen (Chamberlain et al.,
2004). Most importantly, the quality of bone synthesised by the altered MSCs 
was improved, as evidenced by the results of a standard assay in which the 
MSCs were infused into ceramic cubes and then implanted into 
immunodeficient mice (Chamberlain et al., 2004).
In another study, Moutsatos and colleagues used MSC expressing an
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inducible BMP-2, and showed that these cells could both form and 
regenerate bone tissue in vivo and in vitro (Moutsatsos et ai., 2001).
Other advances include the ability to grow MSC in a mineral matrix 
containing ground coral exoskeleton and graft them into defective long bones 
in a sheep model (Kon et al., 2000). The purpose for using a matrix is that it 
already has an open porosity similar to bone and is biologically compatible 
and resorbable. The combination of MSC plus matrix resulted in bone union 
with lamellar cortical medullary canal morphogenesis in some of the animals 
tested (Petite et al., 2000). In other studies, MSCs implanted on a 
hydroxyapatite/tricalcium phosphate matrix or alone, have hastened bone 
formation when sited in craniofacial and long-bone defects (Mankani et al., 
2001; Tsuchida et al., 2003).
MSCs were also used to decelerate (if not reverse) degeneration of 
intervertebral discs (Sakai et al., 2003). Autologous rabbit MSCs grown in a 
type-ll collagenous matrix were used to replace degenerated discs in these 
animals. Treated discs showed little alteration from non-operated/normal 
discs, with intense extracellular matrix staining using Safranin O for 
extracellular proteoglycans, while untreated/degenerating discs had 
progressive vacuolation of nucleus pulposus cells over time, inner annulus 
fibrosus collapse and extensive fibrosis and disc flattening (Sakai eta!.,
2003).
1.5.2 - MSCs into cardiomyocytes
Myocardium has been another tissue, which has been an active 
experimental target for systemic or site-directed MSCs cellular therapy. 
MSCs appear to possess unique properties that may allow for convenient 
and highly effective cell therapy. Indeed, these cells have been shown to 
improve myocardial function in animal models of acute myocardial infarction 
(Orlic et al., 2001; Shake et al., 2002; Toma et al., 2002). Although MSCs 
can be used allogeneically and delivered systemically only very few studies 
have convincingly demonstrated cardiomyocyte differentiation and functional 
integration of these cells into infracted regions. The differentiation into a
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cardiomyocyte-like phenotype when implanted into healthy myocardium was 
only observed in a few studies (Orlic et al., 2001; Toma et al., 2002).
Martin and his colleagues (Shake et al., 2002) have demonstrated that 
after injection into infarcted myocardium, engrafted MSCs could differentiate 
toward a myogenic lineage, as evidenced by expression of muscle-specific 
proteins including: a-actinin, troponin-T, tropomyosin, myosin heavy 
chain-MHC, phospholamban, and other muscle-specific proteins (Shake et 
al., 2002). Additionally, the presence of connexin-43, a protein responsible 
for intracellular connection and electrical coupling between cells, was also 
observed in those studies, further suggesting cardiomyocyte differentiation. 
However, engrafted MSCs in the infarct areas did not show a complete 
myogenic differentiation with mature sarcomeric organisation, intercalated 
discs, etc. This is in contrast to the observations seen when hMSC were 
injected into viable, adult, non-infarcted murine myocardium (Toma et al.,
2002). The lack of extensive myocytic differentiation in infarcted heart may 
be due to the different local extracellular milieu in driving differentiation of 
MSC.
MSCs can also be readily transduced by a variety of vectors and 
maintain transgene expression after in vivo differentiation. Transgene 
expression by MSCs may ultimately be used to enhance cell engraftment or 
the extent of differentiation. Mangi et al. used a retroviral vector to 
overexpress the prosurvival gene Akt in MSCs before implantation into 
infarcted rat myocardium (Mangi et al., 2003). The overexpression of Akt 
increased MSC survival and prevented pathologic remodeling by reducing 
intramyocardial inflammation, collagen deposition and cardiac myocyte 
hypertrophy with improvement in cardiac output (Mangi et al., 2003).
Accumulative data suggest that several mechanisms other than 
cardiomyocyte replacement might contribute to minimise or even reverse the 
post-myocardial infarction tissue. These include: induction of angiogenesis, 
decrease in apoptosis and increase in collagen production. Recent data from 
Kinnaird et al. suggests that the mechanism of MSC-mediated improvements 
may reside in their ability to secrete a variety of angiogenic cytokines (FGF,
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VEGF, matrix metalloproteinases, IL-1, angiopoietin, etc), many of which are 
upregulated under hypoxic conditions (Kinnaird et al., 2004). In another 
report, the authors demonstrated that implanted porcine MSCs express vWF, 
VEGF and other proteins indicative of angiogenesis, in addition to smooth 
muscle actin (sma) (Davani etal., 2003; Tomita etal., 1999).
1.5.3 - MSCs into skeletal myocytes
Much less is known about the capacity of MSCs in contributing to 
skeletal muscle in comparison to myocardial muscle in vivo. Luyten’s group 
conducted the first demonstration of skeletal muscle repair by hMSCs. In this 
case the authors used synovial membrane derived MSCs and showed that 
these cells have myogenic differentiation capacity in the nude and Duchenne 
muscular dystrophy (mdx) mouse models. When these cells were implanted 
into a regenerating nude mouse after cardiotoxin administration, they 
contributed to myofibres and to long-term persisting functional satellite cells 
(De Bari et al., 2003). In this study no evidence of nuclear fusion hybrids was 
observed between donor human cells and host mouse muscle cells (De Bari 
et al., 2003). Also, when administrated into immunosuppressed mdx mice, 
hMSCs were able to rescue some of the pathophysiological features of mdx 
mice muscles (De Bari et al., 2003). A recent report, Dezewa et al. reported 
that myogenic differentiation from human and rat MSCs was achieved by 
Notchl intracellular domain gene transfer and administration of certain 
trophic factors (Dezawa et al., 2005). The methods employed in this study 
could systematically and efficiently induce muscle lineage cells with high 
purity from a large population of MSC. The induced population effectively 
differentiated into mature myotubes with some persisting satellite cells that 
continued to function in host muscle to restore degenerating muscles in the 
absence of repeated transplantation (Dezawa etal., 2005).
27
1.5.4 - MSCs into neuroectodermal cells
Only a few studies have shown beneficial effects of MSCs in central 
nervous system and spinal cord injury (Hofstetter et al., 2002; Lu et al., 2001; 
Wu et al., 2003). One of the first demonstrations of MSCs contribution to 
neuroectodermal cells in vivo was a study performed by Kopen et al. in which 
5-bromo-2-deoxyuridine (BrdUrd) labelled muMSCs were injected directly in 
neonatal mouse brains. Injected cells were able to give rise to astrocytes (co­
expressing BrdUrd and GFAP, glial fibrillary acidic protein) as soon as two 
weeks after transplantation (Kopen et al., 1999). In a more recent study by 
Schuchman and his colleagues they performed direct intracerebral 
transplantation of MSCs in a progression of neurological disease mouse 
models (Jin et al., 2002). The mice (knockout mouse model of types A and B 
Niemann-Pick disease, NPD; ASMKO mice) have a lysosomal storage 
disorder resulting from loss of acid sphingomyelinase (ASM) activity. 
Syngenic MSCs were transduced with a retroviral vector overexpressing 
ASM and were injected into the hippocampus and cerebellum of 3 weeks old 
ASMKO pups. The authors showed that transplanted cells were able to 
migrate away from the injection sites and survived at least 6 months after 
transplantation (Jin et al., 2002). The most important finding of their study 
was the observation that most of the mice survived for more than 7 months, 
while the untreated animals did not. Although overall ASM activity detected in 
brain homogenates was low, surviving Purkinje cells contained the 
retrovirally expressed human enzyme and transplanted animals showed a 
reduction in cerebral sphingomyelin (Jin et al., 2002). A follow-up study from 
the same group suggests that the degenerative microenvironment of Purkinje 
neurons in the NPD cerebellum modulates the cell fate switch of BM-MSCs 
via cell fusion (Bae et al., 2005). Nevertheless, these results reveal for the 
first time the potential of treating neurodegenerative lysosomal storage 
disorders by intracerebral transplantation of bone marrow-derived MSCs.
In another study Dewaza et al. showed a highly efficient and specific 
induction of cells with neuronal characteristics, without glial differentiation, 
from both rat and human MSCs using gene transfection with Notchl
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intracellular domain (NCID) and subsequent treatment with bFGF, forskolin 
and ciliary neurotrophic factor. MSCs expressed markers related to neural 
stem cells after transfection with NICD, and subsequent trophic factor 
administration induced neuronal cells. Some of them showed voltage-gated 
fast sodium and delayed rectifier potassium currents and action potentials 
compatible with characteristics of functional neurons (Dezawa et al., 2004). 
Further treatment of the induced neuronal cells with glial cell line-derived 
neurotrophic factor (GDNF) increased the proportion of tyrosine hydroxylase- 
positive and dopamine-producing cells (Dezawa et al., 2004). Moreover, the 
authors also showed that after transplantation of these GDNF-treated cells 
into a rat model of Parkinsons disease, there was an improvement in 
apomorphine-induced rotational behaviour and adjusting step and paw- 
reaching tests of the animals tested (Dezawa et al., 2004).
Two reports have described the use of MSC transplantation in models 
of peripheral nerve injury. Dezawa et al. described the in vitro expression of 
the glial-cell markers p75, S100, GFAP and 04 by rat MSCs following 
exposure to a cocktail of growth factors and integration of such cells in the 
regenerating growth of the rat sciatic nerve. Myelination of regenerated fibres 
was recognised using confocal and immunoelectron microscopy on the 
transplanted animals (Dezawa etal., 2001). Also, Cuevas etal. described the 
migration and differentiation of MSCs following injection of cultured 
undifferentiated cells into the site of a sciatic nerve axotomy repair (Cuevas 
et al., 2002).
Finally, in the rat model of spinal cord injury, site-directed application 
of MSCs has been shown to improve the neurological outcome in two studies 
(Chopp et al., 2000; Deans and Moseley, 2000). In both studies, rare donor 
cells expressing neural markers can be identified, but the more likely effect is 
related to the production of trophic factors by the MSCs. A second interesting 
observation and possible mechanism is the formation of "guiding strands" 
that bridge the epicenter of the injury and promote directed growth of new 
axons (Hofstetter et al., 2002).
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1.5.5 - MSCs into hepatocytes and pneumocytes
It is important to mention that MSCs have also been shown to 
contribute to different types of epithelia in vivo. Although only less than a 
handful of studies have been reported to date, those that are available in the 
literature have shown quite convincingly that MSC produce such unorthodox 
potentials.
Ortiz et al. showed that after systemic administration of MSCs from 
male bleomycin (BLM)-resistant mice into female BLM-sensitive recipients, 
engrafted male cells were found to be localised in areas of BLM-induced 
injury and exhibited an epithelium-like morphology. Moreover, purification of 
type-ll epithelial cells from the lungs of transplant recipients resulted in a 3- 
fold enrichment of donor-derived cells as compared with whole lung tissue 
(Ortiz et al., 2003). The authors also showed that MSC administration 
immediately after exposure to the BLM also significantly reduced the degree 
of BLM-induced inflammation and collagen deposition within lung tissue 
(Ortiz et al., 2003). Collectively, these studies demonstrate that murine MSCs 
home to the lung in response to injury, adopt an epithelium-like phenotype, 
and reduce inflammation and collagen deposition in lung tissue of mice 
challenged with BLM.
Hepatic contribution of MSCs was demonstrated in a xenotransplant 
setting. hMSCs were administrated directly to allylalcohol treated rat livers 
and hepatocyte-like cells were detected by immunostaining for human- 
specific alpha-fetoprotein (AFP), albumin (Alb), cytokeratin 19 (CK19), CK18 
and asialoglycoprotein receptor (AGPR) and also confirmed by reverse 
transcription-polymerase chain reaction (RT-PCR) for expression of AFP 
(alpha-foetal protein) and Alb mRNA (Sato et al., 2005). In this study, cell 
fusion was not likely to be involved since the authors showed that both 
human and rat chromosomes were independently identified by fluorescence 
in situ hybridisation (FISH) (Sato et al., 2005). The differentiation appeared to 
follow the process of hepatic ontogeny, reprogramming of gene expression in
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the genome of MSCs, as evidenced by expression of the AFP gene at an 
early stage and the albumin gene at a later stage (Sato et al., 2005).
1.6 - Hierarchical organisation of MSC compartment
Some of the examples given previously suggest a non-linear 
relationship between the putative mesenchymal stem cell and its end-stage 
mature phenotypes. The concept of proliferative hierarchy has been 
developed to explain structured cell populations in a tissue, involving stem, 
committed and mature cells (Booth and Potten, 2000; Niemann and Watt, 
2002; Weissman etal., 2001). This concept, which (if) is applicable to the 
vast repertoire of bone marrow-derived mesenchymal stem/progenitors, is 
based on the assumption that proliferation, differentiation, and maturation 
are, in principle, independent. However, populations of committed cells can 
also divide and mature, showing intermediate properties between stem cells 
and functional mature cells. Therefore, the notion of sternness of what is 
currently defined as a mesenchymal stem/progenitor population is not a 
property of a particular cell-type, but a spectrum of capabilities of different 
cell-types within a population. A few reports have attempted to draw a 
scheme for a proliferative hierarchy in mesenchymal stem/progenitors, in 
which most of them have proposed a hierarchy for osteoprogenitors, involved 
in bone cell development (Gronthos et al., 1999; Herbertson et al., 1995; 
Richard et al., 1996), as discussed below.
The bone marrow MSC population shares some properties with 
fibroblastic cells such as expression of matrix proteins and, interestingly, 
some markers of myofibroblastic cells (by expressing smooth muscle actin; 
SMA) and some characteristics of endothelial cells such as endoglin and 
MUC-18 (Filshie et al., 1998). Therefore, some authors claimed that the true 
"mesenchymal stem cell" can be isolated using rather standard procedures 
and characterised using a long list of indeterminate markers as just 
mentioned (Barry et al., 2001; Deschaseaux et al., 2003; Filshie et al., 1998; 
Gronthos et al., 1995; Lodie et al., 2002). However, despite this putative 
"purification" and extensive characterisation, the resulting population was no
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more "pure" than multi-colony-derived strains isolated by simple, short-term 
adherence to plastic (Barry et al., 2001; Deschaseaux et al., 2003; Caplan et 
al., 1994; Filshie etal., 1998; Gronthos etal., 1995; Lodie etal., 2002).
In summury, all data reported to date have strengthened the 
concept/speculation that cultures of bone marrow-derived MSCs are not 
homogenous, but consist of a mixture of uncommitted and committed 
progenitors exhibiting divergent differentiation properties. However, the ability 
to isolate the subset of marrow mesenchymal cells with the most extensive 
replication and differentiation potential would naturally be of utmost 
importance for both theoretical and applicative reasons.
1.6.1 - Uncommitted stem/progenitors in MSC cultures
When examining cultures of bone marrow-derived MSCs on the basis 
of cellular proliferative status, they appear to be non-homogenous. The work 
performed by Colter et al. has shown that in stationary cultures of bone 
marrow, MSCs contain a minor population of small and agranular cells (RS-1 
cells) with a low capacity to generate colonies and are negative for the 
expression of the cell cycle-specific antigen Ki-67 (Colter et al., 2000). 
Quiescent RS-1 cells express an antigenic profile that is different from that 
displayed by the most abundant, fast-growing and committed precursors 
found in expanded cultures of MSCs (matureMSCs). By studying a 
precursor-product relationship between RS-1 and other cell-types, the 
authors came to the conclusion that the high expansive capacity of 
matureMSCs depends on the presence of RS-1 cells (Colter et al., 2000). 
Although it has not been proven, the authors suggested that RS-1 cells might 
cycle under stimulation of factors secreted by the most mature mesenchymal 
progenitor cells. Thus, it seems that RS-1 cells may represent an ex vivo 
subset of recycling uncommitted cells (Colter et al., 2000).
Additionally cells in the quiescent state seem to represent a population 
of uncommitted mesenchymal cells, since they do not express the 
osteogenic and adipogenic commitment markers (Colter et al., 2000); 
Pittenger et al., 1999) Cbfa-1 and PPAR-y, respectively. Also, after prolonged
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exposure to foetal bovine serum (FBS), the slow-proliferating quiescent cells 
give rise to committed precursors that grow quickly and terminally 
differentiate (Pittenger et al., 1999).
Additional evidence came from studies using isolated cell populations 
derived from foetal rat calvaria. The isolated clonally derived population, 
clone RCJ 3.1, can differentiate in a time-dependent sequence into four 
mesenchymal phenotypes. This progression, which was elicited by 
stimulating the cells only with osteogenic differentiation medium, gave rise to 
multinucleated muscle cells at day-9, adipocytes at day-12, chondrocytes at 
day-16, and mineralised bone nodules at day-21 (Grigoriadis etal., 1990). 
Together, it has been shown that a population of cells from foetal rat 
periosteum, isolated on the basis of granularity (S cells), exhibit various 
properties of uncommitted mesenchymal progenitors. Thus, S cells are slow 
cycling, do not express differentiation-associated markers, and when grown 
in culture, generate cartilage, adipose, smooth muscle, and bone phenotypes 
(Ghilzon et al., 1999; Zohar et al., 1997). Altogether, these findings 
demonstrate that despite ex vivo manipulation and subcultivation, cultures of 
so-called “MSCs” contain a rare subset of uncommitted cells displaying 
features of true progenitor or stem cell features.
1.6.2 - Committed progenitors in MSC cultures
In addition to uncommitted mesenchymal progenitors, several groups 
of committed progenitors can be found in cultures of bone marrow-derived 
MSCs. Muraglia et al. investigated the differentiation potential of different 
clonally derived committed progenitor populations and demonstrated that 
approxim ately 30% of all clones exh ib it a tri-lineage 
(osteogenic/chondrogenic/adipogenic) differentiation potential, while the rest 
exhibit either a bi-lineage (osteogenic/chondrogenic) or a pure osteogenic 
potential (Muraglia et al., 2000). Clones with a differentiation potential limited 
to the osteogenic/adipogenic or to the chondrogenic/adipogenic phenotypes, 
as well as pure chondrogenic and adipogenic clones, were not seen
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(Muraglia et al., 2000). These observations have been extended by other 
studies showing the existence of a quadripotential mesenchymal progenitor 
(clone BMC9), which under appropriate conditions differentiates into 
osteoblasts, chondrocytes, adipocytes and haematopoietic-supporting 
stroma (Dennis etal., 1999).
Other experimental approaches have been followed to gain insight 
into the characteristics and differentiation potential of bone-resident 
mesenchymal progenitors. In one of these studies, four cellular subsets were 
sorted from primary cultures of normal human bone, according to the 
differential pattern of expression of the stromal precursor cell marker Stro-1 
and the osteoblastic marker alkaline phosphatase (Gronthos et al., 1999). 
The Stro-1 pos/APne9 subset exhibited a pre-osteoblastic phenotype, as 
evidenced by a reduced ability to form a mineralised bone matrix and by the 
lack of expression of bone sialoprotein, osteopontin and parathyroid hormone 
receptor (Gronthos et al., 1999). The other subsets correspond to 
intermediate and fully differentiated osteoblasts. As expected, after sorting 
and re-culturing, only cells in the Stro-1 pos/APneg subpopulation were able to 
give rise to all of the four subsets of Stro-1/AP cells present in the primary 
culture (Gronthos et al., 1999). Thus, these results have demonstrated that 
cultures of human bone are not homogenous, but on the contrary, they 
include committed osteoprogenitors as well as end-stage differentiated 
osteoblasts.
1.6.3 - Multipotent Progenitor Cells in BM
Despite the valuable efforts made by many groups to identify and 
isolate the “true” multipotent stem cell from adult BM, to date the putative 
MSC with the capacity of differentiating into different cell-types both in vitro 
and in vivo (not only to the conventional mesenchymal lineages but also to 
visceral mesoderm, endothelial and neuroectoderm cell-types) is yet to be 
found in vivo. From all the studies reported, it seems that the closest 
candidate is the RS-1 cells described by Prockop’s group. However, the
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multipotent capacity of these cells both in vitro and in vivo into different cell- 
types of the three germ-line layers, remains to be shown.
Verfaillie’s group has recently described a cell-type that has not only 
multi- but also pluripotent features. These cells, termed multipotent adult 
progenitor cells (MAPCs), express markers of ES cells such as Rex-1, Oct-4 
and SSEA-1. These cells were obtained by initial co-purification with MSCs 
and grow as adherent cells in vitro from postnatal marrow (and other organs) 
of mice, rats and humans (Jiang et al., 2002a and 2002b). However, unlike 
MSCs, MAPCs can be cultured for more than 120 population doublings in 
vitro in a relatively nutrient-poor medium (Jiang et al., 2002a) with expression 
of telomerase and maintenance of telomere length (Reyes et al., 2001).
Clonal populations of MAPCs were established and could be 
differentiated into endothelium by culturing with VEGF with the acquisition of 
functional features in vitro (Reyes et al., 2002). Endodermal cell-types 
induced by FGF-4 and HGF showed functional characteristics of 
hepatocytes. These differentiated cells expressed the early hepatocytic 
markers HNF-1, HNF-3 and GATA-4 after 4 days and the late hepatic 
markers CK18 and albumin after 14 days post-induction (Schwartz et al.,
2002). A convincing demonstration of the functionality of the cells was 
provided by different assays such as urea and albumin productions, 
cytochrome activity, LDL (low density lipoprotein) uptake and 
gluconeogenesis (Schwartz et al., 2002). When murine MAPCs were 
cultured with a series of bFGF, EGF and other neurotrophic factors, different 
mature neuronal phenotypes could be observed (Jiang et al., 2003). 
Thorough analysis revealed that some of the cells expressed markers of 
dopaminergic neurons, others expressed markers of serotonergic and 
GABAnergic neurons. Co-culture of these cells with primary mouse 
astrocytes further matured the cells and led to a more elaborate array of 
axons. In a series of patch-clamp recordings the authors showed occurrence 
of spiking behaviour that could be attributed to voltage-gated sodium 
channels and also suggested the occurrence of synaptic events (Jiang et al.,
2003).
MAPCs also display their broad differentiation potential in vivo. For 
these assays, MAPCs were derived from ROSA 26 mice, which express
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galactosidase under a ubiquitous promoter, so that cells from these animals 
could be tracked. ROSA-26-derived MAPCs injected into murine blastocysts 
resulted in chimeric mice with ROSA-26 cells contributing to nearly all 
somatic tissues, including brain, lung, myocardium, liver, intestine and kidney 
(Jiang et al., 2002a). After intravenous administration into a sublethally 
irradiated immunodeficient mouse, MAPCs differentiated to varying degrees 
into haematopoietic cells in the marrow, blood and spleen and into epithelial 
cells in the liver, lung, and intestine. However, it is not yet clear whether 
MAPCs are a distinct, rare subpopulation of MSCs normally present or 
whether their in vivo and in vitro potential are a phenomenon developed 
under unique in vitro cell culture conditions.
Cell populations with comparable potentials have been 
isolated/expanded from cord-blood cells by Kogler et al. and BM cells under 
hypoxic culture-conditions by D’lppolito et al. In the first case, the authors not 
only showed that these cord blood derived multipotent cells have 
differentiation capacities in vitro, but also in vivo, including haematopoietic 
reconstitution (Kogler et al, 2004). However, in both studies, cells were not 
prospectively identified/isolated and therefore their true existence remains to 
be proven (D’lppolito et al., 2003; Kogler et al, 2004).
1.7 - Aims of the thesis
All the studies reported and described here have shown that a 
putative stem, or very primitive progenitor, might exist in the bone marrow 
derived adherent cultures (and most possibly in vivo), but it is still yet to be 
identified and characterised. The aim of this thesis was to further examine 
the murine mesenchymal cultures with the objective to identify this “true” 
stem cell and provide a detailed characterisation of it.
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Chapter 2 - Materials and Methods
2.1 - Isolation, enrichment and expansion of muMSCs
Bone marrow cells were collected by flushing the femurs, tibias and 
iliac crests from 6 to 12 weeks old of Non-Obese-Diabetic/Severe-Combine- 
Immunodeficient (NOD/SCID), NOD/SCID-p2nuH and C57BL6/J mice with 
phosphate-buffered saline (PBS; CRUK central cell services) supplemented 
with 2% of foetal bovine serum (FBS; Gibco, Paisley, UK; PBS-2%). Bone 
marrow cell suspensions were submitted to red cell-lysis using 3x the initial 
volume of ammonium chloride solution (NH4CI; Stem Cell Technologies, 
Vancouver, Canada) for 10 min on ice. After this time, FBS was added to the 
suspensions to neutralize the NH4CI. Red cell-depleted bone marrow 
mononuclear cells (BMMNCs) were plated at a density of 106 cells/cm2 in 
Murine Mesenchymal Medium with Murine Mesenchymal Supplements 
(Stem Cell Technologies), further supplemented with 100 lU/ml penicillin and 
100 (xg/ml streptomycin (pen/strep, Gibco). For a 25-cm2 tissue culture flask, 
5 ml of medium was used and the volume of medium was changed 
proportionally according to the area of the flasks/plates used. Non-adherent 
cells were eliminated by a half medium change at day 3 and the whole 
medium was replaced weekly with fresh medium.
The cells were grown for 2 to 3 weeks until attaining almost 
confluency. The whole adherent fraction was then detached by trypsinization 
using a 0.25% trypsin/versine solution (CRUK, central cell services) for 5-10 
min at 37 °C. Once detached, FBS was added to the cell suspensions to 
neutralize the reaction and cells were collected, spun down at 1300 rpm for 7 
min and the supernatant was discarded (unless stated, these centrifugation 
conditions were applied for all methodologies concerning “cell washing and 
passing”). Cells were then re-plated using a 1:3 dilution factor. Subsequent 
passing and seeding of the cells was performed at a density of 5000 
cells/cm2. The passage number of cultured (unpurified, Px or enriched, 
purPx) MSCs refers to the number of times that the cells have been
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trypsinized. To enrich MSCs, adherent cells from passage 2 (P2) and 3 (P3) 
were stained with rat anti-mouse CD45-CyChrome and CD11b-PE or a 
combination of CD45 and biotin-conjugated Lineage (Lin) Cocktail Antibodies 
followed by streptavidin-PE (see in the Appendix III section for information on 
the antibodies used). To eliminate the hematopoietic contaminants, the 
negative fraction from both cell surface antigens was sorted using the 
fluorescence activated cell sorter Vantage (FACS; Becton-Dickinson, Oxford, 
UK).
2.2 - Isolation and expansion of SSEA-1pos-MSCs
Six weeks old NOD/SCIDs were used to isolate SSEA-1pos -MSCs in a 
similar fashion as described above. SSEA-1pos cells were isolated from 
cultures already devoid of hematopoietic contaminants. Isolation of SSEA- 
1pos-MSCs cells was performed using FACS sorting after the cells had been 
labelled with SSEA-1 antibody followed by anti-mouse IgM-PE antibody. For 
SSEA-1pos-MSCs enrichment, anti-PE immunomagnetic beads were used 
according to the manufacturer’s instructions (Miltenyi Biotech, Bergisch 
Gladbach, Germany). For clonal analysis, single SSEA-1pos cells were sorted 
from the CD45/CD11bneg fraction of passage 1 (P1) of adherent cultures into 
single wells of a 96-well plate. To determine whether SSEA-1 pos-MSCs could 
be isolated prospectively from mouse bone marrow, lineage negative cells 
were obtained first from BMMNCs using the Murine Lineage Cocktail from 
Stem Cell Technologies according to the manufacturer’s instructions. 
Lineage (Lin) negative cells were further stained with anti-CD31, anti-CD45 
and anti-SSEA-1 and cells were analysed based on Linne9/CD45neg/CD31ne9 
and SSEA-1pos expressions.
Culturing SSEA-1 pos-MSCs in MAPC conditions was performed as 
described by others (Jiang et al., 2002 and 2003). Briefly, SSEA-1 pos-MSCs 
were cultured on 1 p,g/cm2 of fibronectin (Sigma, Dorset, UK) and cells were 
maintained at a density of 500 to 2500 cells/cm2. For a 25-cm2 tissue culture 
flask, 5 ml of medium was used and the volume of medium was changed 
proportionally according to the area of the flasks/plates used. MAPC medium
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consisted of 60% DMEM-Low Glucose (Dulbecco’s modified Eagle medium, 
Gibco) and 40% MCDB-201 containing: 1x insulin-transferrin-selenium (ITS), 
1x linoleic-acid-bovine-serum-albumin (LA-BSA), 10‘9 M dex, 10‘4 M ascorbic 
acid 2-phosphate (all from Sigma), 2% FBS, 1000 units/mL of mLIF (murine 
Leukemia Inhibitory Factor; Chemicon, Temecula, CA, USA), 10 ng/mL of 
hPDGF-BB and 10 ng/mL of mEGF (both from Peprotech, London, UK).
2.3 - Immunostaining of cell surface and intracellular 
antigens for flow cytometry analysis
For cell surface antigens, aliquots of different cell suspensions (50 pJ 
containing 104 to 106 cells) were stained with antibodies (see Appendix III for 
antibody concentrations used) at 4°C for 30 min. After this period, cells were 
washed with 2 ml of PBS-2% (unless stated, a similar volume of washing 
solution was applied for all methods concerning “cell washing”). When 
secondary and tertiary incubation steps were required, cells were stained in a 
similar fashion with two washes in between steps. Finally, cells were 
resuspended in 300-500 [i\ of PBS-2% containing DAPI (4',6-diamidino-2- 
phenylindole; Molecular Probes, Eugene, Oregon, US) at the final 
concentration of 10 ng/ml, for exclusion of dead cells.
For intracellular antigens, aliquots of different cell suspensions (50 i^l 
containing 105 to 106 cells) were fixed by adding 500-1000 i^l (depending on 
the cell suspension concentration) of a 2% PFA (paraformaldehyde; Sigma) 
solution for 10 min at RT (room temperature) then permealized with PBS 
containing 0.1% Triton-X-100 (using same volume as fixation step; Sigma) 
for 10 min at RT. Cells were washed twice between steps. Each antibody 
incubation step was performed at RT for 30 min or 1 h for cytoplasmic or 
nuclear antigens respectively. Cells were then washed twice and 
resuspended in 300-500 \i\ of PBS-2% containing DAPI (at the final 
concentration of 10 ng/ml), to visualise the cell populations and exclusion of 
debris. The analysis was performed using an LSR (Becton-Dickinson).
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2.4 - Colony Forming Units-Fibroblast (CFU-F) assay
Red-cell depleted BMMNCs from NOD/SCID, NOD/SCID-p2nu" and 
C57B6/J mice were plated at a density of 5x105 cells/cm2 and cultures were 
maintained as described in Chapter-2.1. On day 14, the medium was 
removed from the wells, washed twice with PBS and fixed in methanol for 10 
min at RT. Giemsa stain (CRUK, central cell services) was applied to the 
cultures at RT for 5 min, rinsed with distilled water (dH20) and colonies were 
counted microscopically.
2.5 - In vitro lentivirus-mediated gene (eGFP) transfer into 
muMSCs
2.5.1 - General description of lentivirus used
Transduction of MSCs was performed with an HIV-1-based self- 
inactivating (SIN) lentiviral vector (pHRSINcPPT-SEW), which carries the 
eGFP (green fluorescent protein) reporter gene under the control of the 
spleen focus-forming virus (SFFV) LTR (gift from Prof. A. Thrasher, Institute 
Child of Health, London-UK). Research Fellow Dr Elena Siapati performed all 
plasmid preparations used in these studies. Briefly, three types of plasmids 
were used to transiently transfect a producer cell line (293T). The plasmids 
consisted of: the first expressing the core proteins and enzymes essential for 
viral replication, reverse transcription and integration (pHRSINcPPT-SEW), 
the second encoding the pseudotype envelope protein (VSVG; vesicular 
stomatitis Virus G envelope, pMDG), and the third containing the c/s-acting 
sequences required for optimal packaging, reverse transcription, and 
integration of the transgene (p8.91).
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2.5.2 - Brief description of plasmid preparation
L-ampicillin-agar plates (CRUK, central cell services) with transformed 
bacteria (by caesium chloride method) containing the different types of 
plasmids, already available in the laboratory, were used for DNA plasmid 
preparation. A single colony from each plate was removed with the aid of a 
loop and inoculated in 2 ml of fresh starter culture medium (L-Broth; CRUK 
central cell services) containing the selective antibiotic (L-ampicillin at 
concentration of 50 ng/ml) and incubated for overnight (ON) at 37 °C in a 300 
rpm shaker. Next the whole amount of inoculum was diluted with a litre of 
culture medium (a 1:500 dilution) and then left to grow for ON using the same 
conditions. At the end of the incubation time, the bacterial cells were 
harvested by centrifugation at 6000 g for 15 min at 4 °C and the pellet was 
used for DNA plasmid extraction. All plasmid extraction was performed using 
the Qiagen Plasmid Mega kit according to the manufacturer’s instructions.
2.5.3 - Brief description of lentivirus preparation
A total of 107 293T cells were seeded in one 150-cm2 flask ON prior to 
transfection. Cells were cultured in DMEM with 10% FBS, pen/strep, and the 
medium was changed 2 h prior to transfection. A total of 100 jxg of plasmid 
DNA was used for the transfection of one flask: 17.5 jxg of pMDG, 32.5 ^g of 
p8.91 and 50 ^g of transfer vector plasmid were added to 5 ml of OptiMEM 
(Gibco) and filtered through a 0.2 \ im filter. 2.5 \i\ of 1 MP E I  
(polyethyleneimine, Sigma) was added in 5 ml of OptiMEM and filtered 
through a 0.2 i^m filter and the two 5 ml solutions were added together and 
left at RT for 20 min.
The cells were washed once in OptiMEM and the DNA plus PEI 
complexes were then added to them. After 4 h of incubation, the medium 
was replaced by fresh complete medium. At 24 h post-transfection, the 
medium was replaced sufficiently enough to cover the cells. On the following 
day, medium was collected and centrifuged at 2500 rpm for 10 min at 4 °C
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and filtered using a 0.45 \im filter. Vector particles were then concentrated 
20- to 100-fold by ultracentrifugation at 23000 rpm for 2-3 h at 4°C. The 
supernatant was carefully decanted off and the pellet was resuspended in 50 
\i\ serum-free X-VIVO-10 medium (BioWhittakerEurope, Verviers, Belgium) 
and kept at -80°C until use. Titration of the virus was carried out using HeLa 
cell line. Briefly, 50000 cells were seeded per well of a 12-well plate in 1 ml of 
complete DMEM and allowed 4 h to adhere. An aliquot of 30 i^l of virus was 
added to a final volume of 1.5 ml of complete DMEM. From this 1:50 starting 
dilution, virus particles were diluted until 1:50000 dilution. To the first well of 
the 12-well plate, 1 ml of unconcentrated virus was added (1:2 dilution) and 
in the second well 0.2 ml of unconcentrated virus was added with 0.8 ml of 
medium (1:10 dilution). To the second row of the plate, 1 ml of each serial 
dilution of virus was added (1:100, 1000, 10000 and 100000). Two wells 
without medium were used as a negative control. The plates were placed in 
the incubator for two days before the cells were detached and analysed by 
flow cytometry. The titre of the virus was determined as follows:
(% of positive cells) x (dilution) x (n° of cells infected)/100
2.5.4 - Lentivirus transduction into muMSC
For transduction, 1x104 purified MSCs from passage 4 (purP4) were 
seeded into individual wells of a 12-well plate. On the following day, virus 
particles were added at multiplicity of infection (M.O.I) of 5, 10, 30 or 50 and 
transduction was performed for 20 h. Cells were harvested on day 1, 3 and 5 
after virus removal and analysed for eGFP expression by flow cytometry.
2.6 - Cell cycle analysis with Hoechst/PyroninY (Hst/PY)
Different cell-types were resuspended at a density of 106 cells/ml in 
Hst buffer containing 5 nmol/ml of Hst (Hoechst33342; Sigma). After 
incubation at 37 °C for 45 min, pyronin-Y (PY) (Sigma) was added to a final 
concentration of 2.5 pg/mlfor an additional 45 min. Cells were washed once,
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resuspended in Hst buffer and then analysed. In some cases, antibody 
staining was performed after the Hst/PY step and was carried out in Hst 
buffer containing the two dyes. In this case, cell suspensions were washed 
with Hst buffer. Pulse processing was used in order to exclude any 
unstained, apoptotic or clumped cells and analysis was performed using the 
LSR.
2.7 - In vitro differentiation culture conditions
MSCs were plated on cover slips at a density of 3000 to 5000 in 
mesenchymal medium for 24h. In studies using enriched SSEA-1 pos-MSCs 
and clonally derived SSEA-1 pos-MSC, cells were plated at a density of 5000 
to 10000 cells/cm2 in MAPC expansion medium for 24h. With the exception 
of chondrogenic differentiation, in all other cases, after attachment the cells 
were washed once with basic differentiation medium (consisting of DMEM- 
low glucose supplemented with 2% FBS and pen/strep) and then replaced 
with basic differentiation medium containing specific differentiation 
supplements. Each specific differentiation medium was changed every 2 to 3 
days and cultures were kept for 14 days with the exception of chondrogenic 
differentiation, in which cells were incubated for 3 weeks. Each specific 
differentiation condition was as follows (all chemicals and cytokines were 
purchased from Sigma and Peprotech respectively):
-osteogenic: 50 mM ascorbic acid 2-phosphate, 100 nM Dex and 10 mM b- 
glycerophosphate;
-adipoaenic: 1^iM Dex, 50 ^M  indomethacin, 500 nM 3-isobutyl-1- 
methylxanthine and 5 ug/ml of insulin or 5% Horse Serum (HS);
-chondrogenic: 105 to 106 cells were pelleted in a 15 ml-conical 
polypropylene tube, supernatant discarded and medium was added slowly to 
the pellet to avoid disturbance. Serum free medium consisted of: DMEM-high 
glucose, 6.25 ug/ml of insulin, 6.25 ug/ml of transferrin, 6.25 ug/ml of
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selenite, 5.33 ug/ml of linolite, 1.25 mg/ml of BSA, 100 nM Dex, 50 ug/ml of 
ascorbic acid 2-phosphate and 10 ng/ml of TGFp3 (transforming growth 
factor-p3);
-myogenic: 10 p,M 5’-azacytidine, 50 pM hydrocortisone and 5% HS for an 
initial 24 h period. Cultures were then maintained in the same conditions 
without 5’-azacytidine;
-visceral mesoderm (hepatocvte-like cells): 10 ng/ml of HGF and FGF-4 
-endothelium: 10 ng/ml of VEGF;
-neuroectoderm (astrocvte/neuronal-like cells): 50 ng/ml of bFGF and 20 
ng/ml of mEGF.
2.8 - Assessment of in vitro differentiation potential of 
different populations of MSCs
2.8.1 - Immunostaining
Cells from different populations of MSC were first washed twice with 
PBS and then fixed in PBS with 4% PFA at RT for 10 min or in ice-cold 
methanol (for structural cytoplasmic antigens) for 2 min. After this time, cells 
were permeabilized with PBS containing 0.1% Triton-X-100 for 10 min. Fixed 
cultures were blocked with PBS with 10% serum (rat and/or goat) for 30 min 
at RT and sequentially stained with primary antibodies at 4°C ON, followed 
by appropriate secondary antibodies for 1h at RT. In-between all steps, cells 
were washed twice with PBS containing 2% of bovine serum albumin (BSA; 
Sigma). The amount of each reagent and washing solution added per well 
(for a 12-well plate) was approximately 500 jxl and 2 ml respectively. When 
both extracellular and intracellular antigen detection was required at the 
same time, cells were firstly fixed as above, and then stained for the cell 
surface antigen for 1h at RT for each antibody-staining step. Cultures were
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then permeabilized and stained for intracellular proteins in a similar fashion 
as described. Finally, cover slips were mounted with Fluorescence Mounting 
Medium (Dako, Cambridgeshire, UK) containing DAPI for nuclear staining.
2.8.2 - Immunocytochemistry
2.8.2.1 - Alkaline Phosphatase detection
Alkaline phosphatase activity was determined as recommended by the 
manufacturer's instructions contained in Sigma kit #85.
2.8.2.2 - Oil Red O staining
Firstly, medium was aspirated off and cultures were washed twice with 
PBS and fixed in 10% Neutral Buffered Formaldehyde (NBF) for 30 min at 
RT. Formalin solution was then removed and cultures were rinsed with dH20 
and then 60% isopropanol was added for 5 min. Isopropanol was then 
poured off and Oil Red O (Sigma) working solution (3 parts of Oil Red stock 
solution with 2 parts of dH20) was added to the fixed cultures for 10 min. 
After this time, cultures were rinsed with tap water until the water was clear, 
counterstained with Mayer’s hematoxylin (Sigma) for 1 min, rinsed with dH20  
and mounted with Glycergel Mounting Medium (Dako).
2.8.2.3 - Chondrogenic pellet processing and staining
Cell pellet was fixed in 10% NBF for 1-24h at RT then immersed into 
70% ethanol until embedded. The technical staff from the CRUK 
Histopathology Unit performed pellet embedding and sectioning. Each 
embedded pellet was cut into 10 pm thick sections. Different types of staining 
were used for chondrogenic differentiation assessment: Alcian Blue, Alizarin 
Red S and Safranin O (all solutions were prepared by the staff of the 
Histopathology Unit). Firstly, sections were de-paraffinized by immersing in
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2x xylene for 10 min, followed by sequential hydrating steps in 4 grades of 
ethanol (100%, 95%, 80%, 70% and 50%) for 2 min each.
For Alcian Blue staining, sections were hydrated to water, stained with 
Alcian Blue solution for 5 min, rinsed with water and counterstained with 1% 
neutral red solution for 1 min. At the end, slides were blot dried, differentiated 
in 100% ethanol, cleared in xylene and mounted with DePex Mounting 
Medium (BDH, Leicestershire, UK).
For Alizarin Red S staining, staining solution was applied for 30 sec to 
5 min, blot dried, differentiated in acetone (20 dips), cleared in xylene and 
mounted with DePex.
For Safranin O, slides were sequentially immersed in a 0.02% Fast 
Green solution for 3 min, 1% acetic acid solution for 30 sec and 0.1% 
Safranin O solution for 5 min. Slides were dehydrated in sequential grades of 
ethanol (70%, 90% and 100%), cleared in xylene and mounted with DePex.
2.9 - Assessment of in vitro functionality of MCSs
2.9.1 - Alkaline phosphatase activity assay
Cells were collected by trypsinization, washed once with PBS and 
pelleted. Cell pellets were lysed in 100 \i\ of AP lysis buffer for 10 min at RT. 
Lysates were spun down for 15 min at 1500 rpm and supernatants were 
collected. Enzyme activity was assayed by adding 200 \i\ of the working 
solution from the Red Microwell Kit (Sigma) to 10 ptl of each sample, for 30 
min at 37 °C, in a single well of a flat 96-well plate. Each supernatant was 
assayed in triplicate and absorbance was measured at 490 nm. AP activity 
was determined by assuming that 1 O.D is equivalent to 64 nmol of p- 
nitrophenol (Phinney et al., 1999). Protein content was determined in aliquots 
of each lysate using the conventional Bradford assay.
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2.9.2 - Calcium quantification assay
Calcium extraction was done by scraping the culture plates with 0.5 M 
of HCI (choric acid), then shaking for 4h at 4 °C (500 \i\ for one well of a 12- 
well plate). Lysates were then spun down at 3500 rpm for 5 min and 
supernatants were collected. Calcium quantification was assayed by adding 
200 \x\ of the working solution from the Calcium Calometric Kit (Sigma) to 10 
\i\ of each sample, for 15 min at RT, in a single well of a flat 96-well plate. 
Each supernatant was assayed in triplicate and absorbance was measured 
at 575 nm. A standard curve with known concentrations of calcium chloride 
(CaCL) was used to plot the absorbance values. Protein content was 
determined in aliquots of each lysate using the Bradford assay.
2.9.3 - IL-1a treatment
Cells were incubated with 100 U/ml of IL-1a (interleukine-1a, 
Peprotech) in serum-free medium for 6h. Cells were then detached from the 
plates, collected and stained with antibodies against MHC-I, ICAM-1, VCAM- 
1 and P-selectin for flow cytometry analysis.
2.9.4 - In vitro angiogenesis assay
Preparation of the extracellular matrix was done using a flat 96-well 
plate according to the manufacturer’s instructions (Chemicon). Cells were 
first detached from their original plates by trypsinization and resuspended in 
serum-free medium containing 10 ng/ml of VEGF at the final concentration of 
2x106 cell/ml. 50 \x\ from each cell suspension was added to a single well and 
cells were incubated for 6-8h at 37°C.
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2.9.5 - Uptake of Low-Density Lipoprotein
Dil-Ac-LDL staining kit was purchased from Biomedical Technologies 
(Stoughton, MA, US) and the assay was performed according to the 
manufacturer's instructions.
2.9.6 - Periodic acid-Schiff (PAS) assay
PAS assay was used to determine glycogen deposition in cells. 
Cultures were washed twice with PBS, oxidized in 1% of periodic acid 
solution (BDH) for 5 min and rinsed thrice with dH20. Afterwards, slides were 
treated with Schiffs reagent (BDH) for 15 min, rinsed with dH20 for 5-10 
min, stained with hematoxylin for 1 min, rinsed with dH20  and mounted with 
Glycergel Mounting Medium.
2.6.7 - Pentoxyresorufin O-Dealkylase (PROD) assay for Cytochome- 
P450 activity
Different cell-types were maintained in their respective conditions in 
the presence or absence of 1 mM of Phenobarbital (Sigma) for 48 h followed 
by treatment with 10 ^M of pentoxyresorufin (Sigma) for 48h. After that 
period cells were washed twice with PBS and assessed using a fluorescence 
microscope.
2.9.8 - Measurement of cytoplasmic Ca2+ increase
Cells were assayed for their response to different neurotransmitters by 
measuring cytoplasmic calcium fluxes, lndo-1 acetoxymethyl ester (lndo-1 
AM, Molecular Probes) stock solution was prepared in DMSO (Sigma) to a 
concentration of 1 mM. Aliquots of the solution were added to the cell 
suspensions (un- and differentiated cells; 106 cells/ml) to a final
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concentration of 1 pM and incubated at 37°C for 1h. After loading, cells were 
washed twice in serum-free PBS, resuspended at 106 cells/ml and analysed 
on the LSR. Specific substances (50 mM of potassium, K+; 50 mM of 
histamine; 50 mM of glutamate; all from Sigma) were added -30 sec after 
fluorescence reading. The basal values were taken from the mean 
fluorescence levels before drug addition. The filter set-up on the LSR for 
lndo-1 (UV excitation only) is for calcium-bound lndo-1 violet FL-5 424/44 nm 
BF filter and unbound lndo-1 green FL-4 530/30nm BF filter. Calcium flux 
was measured as a ratio between calcium bound lndo-1 and unbound or FL- 
5/FL-4 versus time. Full-scale deflection of the calcium flux was measured by 
the addition of lonomycin (10 pg/ml; Molecular Probes).
2.9.9 - 3H-glutamate uptake
3H-glutamate uptake was determined as described by others (Duan et 
a/., 1999; Stanimirovic et al., 1999). Briefly, cultures grown in 24-well plates 
were washed twice with PBS and then equilibrated in Kreb’s buffer (or similar 
buffer with same molarity of choline-CI as sodium substitute, Na+) for 20 min 
at 37°C. 1 p.Ci/ml of L-[G-3H] glutamic acid (Amersham Biosciences, 
Buckinghamshire, UK) (at final concentration of 1 mM) was then added to 
each well and cells were incubated at 37°C for 1h. The reaction was stopped 
by rapid washing twice with ice-cold PBS. Cells were then lysed with 125 \x\ 
of 0.1% Triton-X-100 solution plus sodium hydroxide (NaOH; at final 
concentration of 0.1 M), for a few minutes then neutralized with HCI. The 
radioactivity present in cell lysates was measured by adding 100 i^l of each 
lysate into 5 ml of the Betaplate Scint scintillation fluid (Wallac, Milton 
Keynes, UK) and scintillation was counted using the Beckman LS6500 
counter (Beckman Coulter, High Wycombe, Buckinghamshire, UK). Aliquots 
of the lysates were also assayed for protein content.
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2.9.10 - Glutamine synthetase (GS) activity-colorimetric assay
This assay is based upon the formation of y-glutamylhydroxamate 
from glutamine and hydroxylamine. A coloured complex is then formed with 
ferric chloride, which can be measured colometrically. This is a measure of 
glutamyltransferase which as been shown to reflect GS activity (Duan et a i, 
1999; Stanimirovic etal., 1999). Cell suspensions were washed twice in cold 
PBS and resuspended in GS extraction buffer. Then cells were disrupted by 
sonication (4x 15 s burst at an amplitude of 7-8 nm peak-to-peak) with 
cooling intervals of 1 min. After centrifugation at 7600 rpm for 5 min, 
supernatants were assayed for protein content or for enzyme activity. Cell 
extracts (100 \i\) were incubated at 37°C for 30 min with 400 \i\ of GS 
solution. The reaction was terminated by adding 1 \i\ of ferric chloride (FeCh) 
reagent and absorbance was measured at 535 nm. A standard curve with 
known concentrations of y-glutamylhydroxamate (Sigma) was used to plot 
the absorbance values.
2.10 - Transplantation of eGFP-MSCs and clonally derived 
SSEA-1 pos-MSCs
A total of 41 NOD/SCID mice aged between 8 to 12 weeks old were 
used in two independent in vivo studies. All animal procedures were 
performed in accordance with the CRUK institutional and UK Home Office 
guidelines. eGFP-MSCs (2x106), obtained few days post-viral removal to 
minimize further expansion, were delivered intravenously (i.v.) by tail vein 
injection into each sublethally irradiated mouse (375 cGy using a 137Cs 
source). Mice were then sacrificed on different days and bone marrow and 
specific tissues/organs were collected. In most of the cases, half of each 
tissue was fixed in 10% NBF ON at 4 °C. On the following day, tissues were 
washed and equilibrated in 50% ethanol for 1h and kept in 75% ethanol at 4 
°C until being embedded). Other halves were kept at -20 °C for further 
RNA/DNA extraction. In some cases, small samples of each tissue were also
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cryo-embedded by snap freezing into dry-ice- or liquid nitrogen- cooled 2- 
methylbutane (Sigma) and kept in -80 °C until being processed.
For experiments concerning clonally derived cells, undifferentiated 
SSEA-1pos clone-3 cells (2x105; at 28 doublings) were injected intravenously 
(facial vein) into five 2 days old NOD-SCID-|32nul1 mice. Animals were 
maintained for 8 weeks and then sacrificed and bone marrow and specific 
tissues/organs were collected by snap freezing.
2.11 - Detection of donor-derived cells upon transplantation
2.11.1 - Detection of eGFP transgene by PCR
Genomic DNA was isolated from each tissue by lysing in buffer 
containing SDS (sodium dedecylsulphate) and Proteinase K (PK; all from 
Sigma) followed by phenol-chloroform extraction. After being thawed from 
RNAIater a small piece of each tissue, (-20 mg) was dissected and washed 
twice with 1 ml of PBS. Supernatant was removed and 600 pi of SNET Lysis 
Buffer with PK at a final concentration of 500 mg/ml was added and tissues 
were digested ON at 55 °C with mild shaking (900 rpm). On the following 
day, digested tissue was allowed to cool down to RT, before 4 pi of 100 
pg/ml Rnase (Qiagen) was added and incubated for 30 min at 37 °C. An 
equal volume of phenol:chloroform:isopentane (25:24:1; Sigma) was added 
and vortexed for 20 sec. 550 pi of the supernatant was transferred to a new 
tube and an equal volume of chloroform was added. The mixture was then 
vortexed for 10 sec, followed by centrifugation at maximum speed (-14000 
rpm; max) for 10 min at RT. Supernatant was collected and transferred to a 
new tube with 0.3 volumes of 3 M of sodium acetate (pH 5.2) and 2 volumes 
of ethanol. This was quickly inverted for 5 min for DNA precipitation and then 
centrifuged at RT at max speed. After this time, the supernatant was 
removed and DNA was washed with 1 ml of cold 70% ethanol and 
centrifuged for 5-10 min at max speed. Ethanol was then removed and the
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pellet was let to dry for 15 min before DNA was dissolved in 100 pi of dH20 
on a rotating shaker.
For each 50 pi PCR reaction, 250 ng of genomic DNA was used. 
Amplification was performed using the Taq PCR Core Kit (Qiagen) according 
to the manufacturer’s instructions. Set of primers and their respective 
annealing temperatures and number of amplification cycles information can 
be found in the Appendix II section. Murine glyceraldehyde-3-phosphate 
dehydrogenase (muGAPDH) was used as an internal PCR control.
2.11.2 - Tissue Processing and Immunohistochemistry
All tissues were embedded and sectioned by the technical staff from 
the CRUK Histopathology Unit. Each embedded tissue was sectioned 
between 10 to 15 levels with a 70 to 100 pm gap between each one. Each 
level was serially sectioned at least 4 times. Paraffin sections (4 pm thick) 
were first de-paraffinized by immersing in Histoclear (RA Lamb, East Sussex, 
UK) twice for 10 min each, followed by sequential hydrating steps in four 
decreasing grades of ethanol for 2 min. Tissue sections were immersed in 
water before submitting to antigen retrieval by microwaving for 10 min in 
Antigen Unmasking working solution (Vector Laboratories, Peterborough, 
UK; 3.75 ml in 400 ml dH20). After this time, tissue sections were washed 
twice with dH20  and quenched for endogenous peroxidase for 5 min (PBS 
with 2% H20 2; hydrogen peroxide) and when necessary, for endogenous 
alkaline phosphatase also for 5 min (methanol with 20% acetic acid). Non­
specific staining was blocked with PBS with 10% serum (rat and/or goat) for 
30 min RT and when biotin-labeled secondary antibodies were used, 
endogenous biotin was blocked with the Biotin Blocking System Kit (Dako). 
Staining with primary antibodies was performed at 4°C ON, followed by 
appropriate secondary antibodies for 1h at RT. When biotin-labelled 
antibodies were used, an additional incubation step with streptavidin or 
avidin-conjugated reagent was performed at RT for 30 min. In-between all 
steps, tissue sections were washed twice with PBS with 2% of BSA. 
Immunoreactivity was detected using different peroxidase-based systems or
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alkaline phosphatase-based systems, or a combination of both according to 
the manufacturer’s instructions (Vector Laboratories).
Sections were then washed twice in water for 3 min, counterstained 
with hematoxylin for 2 min, followed by an additional two washes with water. 
Finally, sections were dehydrated twice for 2 min in 95% ethanol, twice for 2 
min in 100% ethanol and twice for 10 min in Histoclear. Slides were mounted 
with DePex Mounting Medium.
For frozen tissues, cryosections (6 pm thick) were fixed in cold 
acetone for 10 min, rinse twice with PBS and blocked with serum and 
endogenous biotin in a similar fashion as above. All staining procedures were 
the same as described but using fluorescent conjugated secondary 
antibodies or tertiary reagents instead. Sections were mounted with 
Fluorescence Mounting Medium (Dako) containing DAPI and visualised 
using a fluorescent microscope (Zeiss AxioVision-2, Zeiss, Welwyn Garden 
City, UK).
2.12 - RT-PCR and quantitative Real-Time RT-PCR
RNA extraction was performed using the RNeasy mini and micro Kits 
(Qiagen) depending on the amount of cells available, according to the 
manufacturer’s instructions. mRNA was reverse transcribed using 
OmniScript (Quiagen) and when low amounts of RNA were obtained 
SensiScript (Qiagen) was used instead. All instructions can be found in the 
manufacture’s booklets. For each 25 pi PCR reaction, 100 ng of equivalent 
cDNA was used. Amplification was performed using the Taq PCR Core Kit 
(Qiagen) according to the manufacturer’s instructions. Murine p-actin was 
used as an internal PCR control. PCR products were verified by running on a 
2% agarose gel.
For quantitative real-time PCR, 25 ng of cDNA was used per PCR 
reaction (25 ml), using SybrGreen Master Mix reagent (Applied Biosystems, 
Cheshire, UK) according to the manufacturer’s instructions. Amplification was 
performed using the ABI Prism 7700 sequence detection system (Applied
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Biosystems). The specificity of the PCR products was verified by running on 
a 2% agarose gel and also using the dissociation curve V1.0 software 
(Applied Biosystems). Set of primers and their respective annealing 
temperatures and number of amplification cycles information can be found in 
the Appendix II section.
2.13 - Western Blot (WB)
2.13.1 - Preparation of cell lysates
Cells were collected by trypsinization, washed once with PBS and 
spun down. Pellet was lysed in 100 pi of WB lysis buffer on ice for 10 min. 
Lysates were spun down at 1400 rpm for 15 min at 4°C. Supernatant was 
then transferred to a new tube and an aliquot was used to determine protein 
concentration. Supernatant was mixed with an equal volume of 2x WB 
sample buffer, boiled for 5 min and cooled down for 5 min at RT.
2.13.2 - Preparation and running the gel
Firstly, resolving gel (10%) and stacking gel were prepared and glass 
plate and spaces were assembled. The running gel was poured to 
approximately 1 cm below the wells of the comb and sealed with the stacking 
gel. When the stacking gel had set, the assemble was placed in the gel rig 
and immersed in running buffer. Prior to running the gel, wells were flushed 
out thoroughly with running buffer. Approximately 15 pi of each sample 
(containing around 15 pg of protein) was loaded into each well and ran with 
constant current (35 - 37 mA with voltage set at >300 V) for 2.5 hr.
54
2.13.2 - Membrane transfer (for BDH semi-dry electroblotter)
For one gel, 6 pieces of extra thick blotting paper (ETBP) and a 
nitrocellulose membrane (Hybond ECL; Amersham Pharmacia Biotech, 
Buckinghamshire, UK) of the exact size of the gel were cut, wet in 1x blotting 
buffer and assembled as follows: 3x ETBP - Blotting Membrane - gel - 3x 
ETBP. The transfer was done for ~1 hr at 0.8 amp/cm2 (8x10 cm gel should 
run with 64 mA for 1-2 hours). When finished, the membrane was immersed 
in blocking buffer ON. On the following day, incubation of primary antibody 
(diluted in blocking buffer) was carried out for 60 min at RT. Membrane was 
washed 3x 10 min with PBS containing 0.05% Tween-20 (Sigma). 
Secondary antibody incubation step was done at RT for 45 min (antibody 
also diluted in blocking buffer). After this time, the membrane was washed 
thrice for 10 min with PBS containing 0.05% Tween-20 (Sigma). Detection 
was carried out using Amersham ECL Kit (Amersham Pharmacia Biotech) 
according to the manufacturer’s instructions.
*Formulation for other solutions used in this study can be found in the 
Appendix I section.
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Chapter 3 - In vitro and in vivo characterisation
of muMSC
3.1 - Brief introduction and description of the study
As described in the general introduction section, MSCs have the 
capacity to give rise to fat, bone and cartilage as well as to neuronal 
progenitors (Woodbury et al., 2000) and muscle (Wakitani et al., 1995) cells 
in vitro making them a potential cellular source for clinical applications in 
regenerative medicine. In vivo studies involving a variety of animal models 
have shown that MSCs may be useful in the repair or regeneration of 
damaged or mutated bone, cartilage, or myocardial tissues (Bianco et al., 
2000; Pereira et al., 1998; Toma et al., 2002). They may also provide a 
useful tool for gene therapy strategies involving genes encoding secreted 
proteins (Bartholomew et al., 2001; Pereira et al., 1995; Duan et al., 2003). 
Although the in vitro differentiation capacities of MSCs have been well 
documented, the same potentials in contributing to different tissue cell-types 
in vivo remain elusive.
So far, most in vivo studies have been performed by targeting a 
specific tissue/organ of interest, normally with the use of an injury model 
(Hofstetter et al., 2002; Kopen et al., 1999; Ortiz et al., 2003). Systemic 
delivery of MSCs is an attractive non-invasive strategy that allows repeated 
administration of large numbers of cells with great potential clinical 
applications (Bianco etal., 2001; Koc etal., 2002). However, (when this study 
started) limited data were available regarding the ultimate fate of systemically 
infused MSCs. In a baboon model Devine et al. suggested that MSCs home 
to a variety of non-haematopoietic organs and may possess the capacity to 
proliferate within these tissues (Devine et al., 2003). hMSCs have been 
shown to be capable of differentiation into multiple cell types following 
peritoneal implantation in fetal sheep (Liechty et al., 2000). Using a partially 
purified muMSCs population Pereira et al. suggested that these cells follow a 
broad initial distribution and their presence could be detected in different
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tissues of the recipient animals few months after transplantation without, 
however, exploring their in vivo differentiation potential (Pereira etal., 1995).
Therefore, the main aim of the first part of this project was to evaluate 
the tissue distribution of muMSCs after intravenous administration and their 
“natural” in vivo differentiation capacities in recipient animals not forced to 
undergo substantial organ degeneration first.
Most of the understanding of MSC biology has been acquired from 
studies on hMSCs. This is one of the uncommon situations where a cell-type 
is better characterised in human than in mice. muMSCs are indeed poorly 
understood, in terms of their phenotype, cell isolation and expansion. 
Although mouse and human MSCs are generally similar in terms of overall 
phenotype and in vitro differentiation capacities, this study showed that 
isolated and expanded muMSCs express different adhesion molecules and 
integrins compared to their human counterparts. Such discrepancies may 
account for and explain potential differences between human and mouse 
MSCs in homing and their in vivo capacity to contribute to specific cell-types 
(Liechty et al., 2002; Devine et al., 2003). Therefore, it was important to 
characterise these cells, reporting detailed and useful information about 
isolation, expansion and phenotype. Ex wVo-expanded muMSCs were then 
tagged by transduction with a lentiviral construct carrying the green 
fluorescent protein (eGFP) and, at various time points after infusion, multiple 
tissues were analysed for the presence of the reporter gene by polymerase 
chain reaction (PCR). Immunohistochemistry was used to screen and 
determine any tissue-specific incorporation of donor-derived cells in the 
recipient animals.
3.2 - Isolation and characterization of muMSCs
Since the ease of isolation and expansion of muMSCs is strain- 
dependent (Phinney et al., 1999; Peister et al., 2004), initially three different 
mouse strains (NOD/SCID, NOD/SCID-(32nul1 and wild-type C57BL6/J) were 
used (mouse strains that were easily available in the lab) to determine the
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frequency of these cells in the bone marrow. muMSCs express a variety of 
cell surface antigens which are shared with different bone marrow-derived 
cell populations. As there is no specific antigen that can be used to directly 
define muMSCs in the bone marrow, the analysis was based on previous 
studies (Phinney et al., 1999; Peister et al., 2004). The murine mesenchymal 
compartment in the bone marrow can be defined as CD45negLinne9CD31ne9 or 
CD45ne9CD11bnegTER119ne9CD31ne9, which is the cellular fraction devoid of 
hematopoietic and endothelial cells (Figure 1). By using this criterion no 
differences in the frequency of MSCs in the bone marrow of these mouse 
strains were found (Figure 1, with 0.16%, 0.16% and 0.1% respectively). 
Moreover, we did not see significant differences in the number of CFU-Fs 
with 1.66±0.38, 1.83±1.51 and 1.83±0.88 colonies/cm2 obtained from 
NOD/SCID, NOD/SCID-p2nu" and C57B6/J BMMNCs respectively (Figure 2).
However, MSCs from the immunodeficient strains exhibited more 
independence from the haematopoietic contaminants for its survival in early 
passages. muMSCs from the immunodeficient strains exhibited higher cell 
expansion and survival potential after removal of the haematopoietic cells 
than those from the wild-type C57BI/6J strain. Thus, all subsequent 
experiments were conducted using NOD/SCID bone marrow. As previously 
reported (Phinney et al., 1999), we observed that MSC cultures were 
contaminated with haematopoietic cells co-expressing CD45 and CD11b, 
which persisted for many passages (Figure 3). Contaminating cells 
consisted of 0.5-2% of B (CD19pos), T (CD3pos), NK (NK1.1pos) cells and 
granulocytes (Ly-eGr*5055) (from 3 to 5 different extractions) but interestingly, 
the majority of the persisting adherent CD45pos/11bpos cells had a more 
progenitor/stem cell phenotype expressing a combination of stem cell 
antigens such as Sca-1, CD34 and CD90. No Ter119pos or CD31pos cells 
were found after the first passage, suggesting that CD45 and CD11b 
markers could be safely used as a routine method for purifying MSCs.
In addition, Sca-1 expression on MSCs was found to increase from 
42±11% (P0), to 44±10.9% (P1), 81.7±12.9% (P2) and finally to >98.5% in 
passage 3, indicating a possible acquisition of this antigen through time in
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Figure 1. Determination of murine mesenchymal compartment frequency in 
the bone marrow
Representative FACS plots analysis of N O D /SC ID  BM M NCs (top plots) stained with 
C D 4 5 /C D 1 1 b /T E R 1 1 9 /C D 3 1  antibodies; the frequency  of m esenchym al 
compartment in the bone marrow can be considered as the negative fraction for 
CD 45 (R 1) with the combination of the other cell surface antigens used here. 
Alternatively, same frequencies can also be determined by using the following 
antibody combination: CD45/Lin/C D31 (bottom plots). By using this criterion no 
differences in the frequency was found between the three mouse strains studied.
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NOD/SCID NOD/SCID-p2nuM C56BL6/J
Figure 2. CFU-F frequency between d ifferent m ouse strains
(a) Representative picture of a 14 days-old NO D/SCID  derived CFU -F colony, (b). 
CFU-F frequency between different mouse strains used in this study. Results shown 
are mean ±s.d from two independent experiments and each one performed in 
triplicate.
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culture. Alternatively, Sca-1pos cells may have a selective advantage in the 
culture conditions used.
After purification (>99.8% purity by FACS), MSCs were 
immunophenotyped by FACS analysis to reveal the expression of stem cell 
antigens like CD34 and Sca-1 but not CD90. Moreover, the cells expressed 
CD9, CD29, CD44, CD73 and CD105. Importantly, MSCs weakly expressed 
or were negative for antigens that play an important role in 
homing/rolling/attachment such as ICAM-1, ICAM-2, E-selectin, P-selectin, 
VLA-5 and VCAM-1 (Table I). Again, these important antigens are found be 
expressed on human MSCs (Deans and Moseley, 2000; personal 
observations).
3.3 - MSCs can be efficiently transduced with eGFP-lentivirus 
vector without losing their in vitro differentiation capacities
After obtaining an enriched MSC population (purP4), cells were 
transduced with an HIV-1-based lentivirus vector carrying the eGFP reporter 
gene. Transduction conditions were optimised by using different multiplicities 
of infection (M.O.I: 5 to 50) and the transduction efficiency was analysed by 
FACS for eGFP. Efficient eGFP expression was observed as soon as one 
day after removal of the virus supernatant (Figure 4a). The highest 
transduction efficiency (>98%) was achieved when an M.O.I 50 was used 
and this expression was maintained days after virus removal (Figure 4b: 5 
days post-virus removal). The percentage of eGFP-expressing cells 
remained virtually unchanged (>96.5%) in subsequent passages (purP4 to 
purP10), which correlated to 35 to 40 days post-transduction. This also 
indicated that the SFFV promoter was not subject to reporter gene silencing 
in these cells. To evaluate whether lentiviral transduction altered the 
differentiation properties of MSCs in vitro, transduced cells were stimulated 
to differentiate into several cell-types. In vitro differentiation studies showed 
that eGFP-MSCs could give rise to different lineages (Figure 5) such as
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Figure 3. Persistence of haematopoietic cell contamination in MSC cultures
The presence of C D 45/C D 11b pos cells in different passages (P 1 -P 3 ) of M SC  
cultures is shown (top plots). Percentages indicate the C D 45/C D 11bneg populations, 
which were considered as the MSC fraction. The C D 45/11bpos haematopoietic cell 
population expressed Sca-1 and different levels of C D 34 and CD 90 (middle and 
bottom plots, respectively). Results shown are mean ±s.d from three independent 
experiments.
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Table I. Immunophenotype of muMSCs
Common Name CD Detection
Hematopoietic Antigens
LFA-3L CD2 Neg
CD3 Complex CD3e Neg
T4 Cell CD4 Neg
Ly-1 CD5 Neg
T8 Cell CD8 Neg
LSP-R CD14 Neg
B Cell Antigen CD19 Neg
CD34 Pos (++)
Leukosialin CD43 Neg
Leukocyte Common 
Antigen CD45 Neg
CD45/B220 Neg
NK Cell Antigen NK1.1 Neg
Erythroid Antigen TER119 Neg
Granulocyte Antigen Ly-6G Neg
Thy-1 CD90 Neg
Stem Cell Antigen Sca-1 Pos (+++)
Early B Lineage 
Antigen AA4.1 Neg
Adhesion Molecules
ICAM-1 CD54 (-/-)
ICAM-2 CD102 Pos (+)
L-selectin CD62L Pos (+)
E-selectin CD62E Neg
P-selectin CD62P Neg
PECAM-1 CD31 Neg
HCAM CD44 Pos (+++)
VCAM-1 CD 106 Pos (+)
MadCAM-1 MadCAM-1 (+/-)
Integrins
LFA-1 a  Chain CD11a Neg
Mac1 CD11b Neg
CR4 a  Chain CD11c Pos (+)
VLA-4 CD49e Neg
VLA-5 CD49e Pos (+)
VLA-01 Chain CD29 Pos (++)
Integrin alEL Chain CD103 Neg
Integrin 07 Chain 67 Neg
LPAM-1 a4p7 Neg
Cytokine Receptors
IL2-R CD25 Neg
IL7-R CD127 Pos (+/-)
c-Kit CD117 Neg
Flk-2/Flk-3 CD135 Neg
Others
Ecto-5'-nucleotidase CD73 Pos (++)
Endoglin CD105 Pos (+)
Tetraspan CD9 Pos (♦++)
MHC I H-2K0 Pos (+++)
M HCII l-Ag' Pos (+)
muMSCs were analysed by FACS with a panel of antibodies using isotype 
controls to set up the initial gates. Depending on the mean fluorescence 
intensity levels observed, samples were scored as Negative (Neg), Positive 
(Pos) borderline (+/-), low positive (+), fairly positive (++) or highly positive 
(+++).
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Figure  4. In vitro  eG FP  e x p re s s io n  by m u M S C s fo llo w in g  le n tiv ira l 
transduction
A highly enriched muMSC population (purP4) was transduced with lentivirus for 20h. 
Analysis for eGFP expression was performed 1, 3 and 5 days post-transduction, (a) 
A representative overlay FACS plot from day 1 with M.O.I: 5 (filled line), 10 (dotted 
line), 30 (dashed line), 50 (grey area) and untransduced control M SCs (light grey 
area) is shown. Cells gated in R1 expressing high levels of eGFP from different time 
points of analysis were plotted in the graph (b). Results shown are mean ±s.d from 
two independent experiments, and each time point was performed in duplicate.
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adipocytes which were visualised with Oil Red O staining (Figure 5b, 5c). 
Chondrogenic capacity was confirmed with Alizarin-red, Alcian-blue (data not 
shown) and Safranin O (Figure 5e) staining indicating the presence of 
sulphated proteoglycans in the micro-pellet formation. The differentiation into 
osteocytes was revealed using staining for alkaline phosphatase and calcium 
production (Figures 5f, 5g). eGFP-MSCs were also able to give rise to 
myocytes with the expression of dystrophin, and fast-twitch myosin (FTM; 
Figure 5h-5k) and astrocytes/neuronal-like cells with the expression of 
GFAP and Tau (Figure 5l-5o). Additionally, expression of eGFP was 
maintained throughout the in vitro differentiation of these cells, indicating 
again that the SFFV promoter was functional after in vitro stimulation. 
Therefore eGFP was used as a means of tracking muMSCs following in vivo 
administration.
3.4 - Distribution of highly transduced eGFP-MSCs into 
different tissues
eGFP-MSCs were injected intravenously into syngeneic mice that had 
been sub-lethally irradiated to prime the bone marrow for homing of infused 
cells. However, sub-lethal irradiation (at the dose of 375 cGy) is a non- 
invasive method known to also cause minor damage to the gut and lungs. 
PCR analysis for eGFP was used to qualitatively evaluate the distribution of 
the transduced donor-derived cells in different tissues of the recipient 
animals (Table II). With the exception of peripheral blood and bone marrow, 
each tissue was subjected to at least three independent genomic DNA 
extractions (from three different parts of the tissue) and three PCR analysis 
respectively. Only when at least two out of the three valid PCR reactions 
were positive for eGFP, was the tissue considered harboring infused cells.
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Figure 5. In vitro differentiation of eG FP-M SCs
Unstimulated eG FP-M SC s were viewed under U V  light (a ). A fter 14 days of 
induction, cells were fixed and stained with Oil Red O (b , c). Chondrogenic 
differentiation was revealed with Safranin O staining (e) with a representative  
section of the micropellet viewed under the fluorescent microscope before the 
staining (d). The osteogenic potential of M SCs was determined by staining for 
alkaline-phosphatase (f) and calcium production (g): stimulated eG FP-M SC s (black 
bar), non-stimulated eG FP-M SCs (grey bar), control-water (light grey bar). Results 
shown are mean ±s.d from two independent experiments, each one performed in 
triplicate. eGFP expression alone on myocyte-like cells (h). Myogenic differentiation 
was confirmed by staining with dystrophin-Cy3 (i, j )  and FTM -C y3 (k). eG FP  
expression alone on astrocyte- (I) and neuronal- (o ) like cells. Neuronal 
differentiation was confirmed by staining with GFAP-Cy3 (m, n) and Tau-TR ITC  (o). 
Overlay of eGFP and dystrophin (j), eG FP and FTM (k) and eG FP with GFAP (n). 
Cells were counter-stained either with haematoxylin (b, c, f) or DAPI (h-j, l-n) or 
methyl green (e). Magnifications: x100 (a, b, f), x200 (d, j, l-n) and x400 (c, e, h, i, 
k, o).
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The distribution of the infused cells was followed from day 1 to 28 
post-transplantation. Surprisingly, no eGFPpos cells could ever be detected in 
the bone marrow, indicating a deficient capacity of muMSCs to home to their 
tissue of origin (also confirmed by FACS analysis). Most probably the lack of 
appropriate adhesion molecules and integrins may have impeded these cells 
to home and seed the bone marrow properly. These data differ from what is 
known about the homing capacity of hMSCs to the bone marrow (Liechty et 
al., 2000; Devine et al., 2003) suggesting that there may be some in vivo 
functional differences between mouse and human MSCs.
PCR analysis showed that the lungs, liver and kidney were the 
primary resident organs of muMSCs, as eGFP could be detected as early as 
one day post-transplantation. Distribution to the muscle, heart, brain and 
spleen did not occur until day 7 after infusion. The fact that eGFP-MSCs 
were found circulating in the peripheral blood at all of the time-points, may 
explain why the reporter gene was able to be detected abundantly in many 
tissues by PCR, while by immunohistochemistry low or no eGFP positive 
cells were detected. Therefore, quantification of the PCR data would not 
necessarily correlate with muMSC differentiation events but would most likely 
represent the extent of circulating cells in the respective tissues.
3.5 - Extensive trapping of muMSCs especially in the lung
An adverse effect observed in the majority of the experimental animals 
transplanted with eGFP-MSCs was retention of these cells in the lung alveoli. 
Aggregates of MSCs were observed in the lung as early as one day post­
transplantation and in many cases persisted thereafter to result in tissue 
damage with development of fibrotic tissue (with cysts containing collagen 
deposition) as well as impaired organ function (Figure 6f). These animals 
exhibited distress, with gradual weight loss and breathing difficulties, and had 
therefore to be sacrificed. Immunohistochemistry was performed on tissues 
where trapped eGFP-MSCs had been observed (e.g. spleen, lungs, and gut), 
and revealed that these cells maintained their MSC phenotype by expressing 
laminin and endoglin (data not shown). Lungs extensively infiltrated with
67
Table II. Percentage of mice that were positive for eGFP in different 
tissues detected by PCR
GUT 17% (1/6) 0% (0/6) 43% (3/7) 17% (1/6) 62% (8/13)
BRAIN 0% (0/6) 0% (0/7) 14% (1/7) 20% (1/5) 8% (1/13)
LIVER 57% (4/7) 17% (1/7) 43% (3/7) 33% (2/6) 69% (9/13)
LUNG 83% (5/6) 17% (1/7) 17% (1/7) 60% (3/5) 54% (7/13)
KIDNEY 43% (3/7) 17% (1/7) 43% (3/7) 43% (3/7) 50% (6/12)
SKIN 29% (2/7) 0% (0/7) 0% (0/5) 25% (1/5) 54% (7/13)
MUSCLE 0% (0/6) 0% (0/6) 17% (1/7) 17% (1/6) 8% (1/13)
HEART 0% (0/7) 0% (0/7) 29% (2/7) 33% (2/6) 8% (1/13)
SPLEEN 0% (0/6) 0% (0/6) 40% (2/5) 43% (3/7) 46% (6/13)
BONE MARROW 0% (0/3) 0% (0/1) - 0% (0/4) 0% (0/5)
PERIPHERAL BLOOD 25% (1/4) 33% (1/3) 25% (1/4) 60% (3/5) 60% (6/10)
Days post-infusion 1 2 7 14 28
Different tissues/organs were collected at various time points (day 1, 2, 7, 14 
and 28) after infusion of eGFP-MSCs into sub-lethally irradiated recipients. 
DNA was extracted from these tissues and analysed for the presence of the 
reporter gene by PCR. Numbers shown indicate mice positive for eGFP over 
total number of mice analyzed. (-) Not performed.
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infused cells did not show reliable staining for lung-specific antigens such as 
lectin Lycopersicon esculentum (Figure 6d), pan-CK or Surfactant Protein C 
(data not shown), due to the extent of tissue damage.
3.6 - Contribution of eGFP-MSCs to different tissue cell-types 
at low frequency
Tissues were subsequently screened for the presence of eGFP- 
MSCs, focusing on the last time point (day 28) for the detection of 
differentiation events by immunohistochemistry. In order to avoid any false 
positive results, a positive event was only considered when eGFPpos cells 
could be detected in the adjacent serial sections and when more than one 
eGFPpos cell could be found on different levels of sections within a particular 
tissue. Isotype control antibody for eGFP was also used to exclude non­
specific staining.
In two animals in which no lung damage was observed, some eGFPpos 
MSCs (Figure 7c, 7d) were detected, which had given rise to cells with 
respiratory bronchiolar epithelial morphology, staining positive with pan-CK 
antibody (Figure 7c).
eGFP-expressing cells with hepatocyte morphology were detected in 
the liver of 3 out of 13 recipient animals. This was a low frequency event and 
in most cases only 1 to 3 positive cells were seen per section, suggesting 
that no or little cell expansion had occurred after the cells reached the liver. 
Interestingly, all positive cells were found near or not far from the blood 
vessels. These eGFPpos cells had not only acquired proper hepatocyte 
morphology (Figure 7e, 7f, 7h) but also stained positive for specific antigens 
such as albumin (Figure 7f) and CK18 (Figure 7h).
In addition, specific eGFPpos cells were observed in the kidneys of 2 
out of 13 mice analysed. These cells had renal epethelial cell morphology 
and were seen at a frequency of 5-10 cells per transverse-section as well as 
on different levels of the tissue (Figure 8b, 8c, 8e).
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Figure  6. T ransplanted  eG FP -M S C s are c ircu la tin g  an d /o r trap p ed  in the  
different tissues
Immnunohistochemistry revealed the presence of infused eG FP-M SC s in different 
tissues. Circulating or trapped (arrows to brown cells) M SCs were found in the 
spleen (a), gut (b) and lung (c). In the lung, trapped cells stained neither for a-sma 
[(red-pink) indicated by the right-side arrow] (c) nor for the lectin Lycopersicon 
esculentum-Cy3 (d, overlay with eGFP). Trapped eG FP-M SCs have caused severe 
lung damage in some of the mice. A representative section of an undamaged lung 
(e) and severely damaged lung (f) from two different mice that were injected with 
eGFP-M SCs (brown cells). Sections were counterstained with haematoxylin (a-c, e, 
f) or DAPI (d). Magnifications: x25 (e, f) x100 (c), x200 (d) and x400 (a, b).
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Immunohistochemistry on serial sections was performed to confirm 
expression of kidney-specific antigens by these eGFP-expressing cells. 
Indeed, these donor-derived cells stained positive for lectins such as Ricinus 
communis or Lotus tetragonolobus (Figure 8b, 8d respectively).
Since muMSCs were previously shown to have the capacity to 
differentiate into skeletal muscle in an injury model (De Bari et al., 2003), a 
more detailed screening was performed at this particular tissue for the 
presence of donor-derived cells. No eGFPpos myofibres were found from 
skeletal muscle isolated from the femur of recipient animals. However, 
infiltrating eGFPpos cells that had acquired myofibroblast-like morphology in 
the skeletal muscle were found (Figure 9a, 9d). These cells were found 
among myofibres, structurally resembled connective tissue and had acquired 
expression of a-sma (Figure 9e, 9f) but not desmin (Figure 9b, 9c) or FTM 
(data not shown). It has been previously reported that some stromal cells 
express a-sma (Peled et al., 1991). However, this antigen was undetectable 
in the MSC population before injection and the trapped cells in the lung did 
not acquire the expression of a-sma (Figure 6c). Therefore, the data suggest 
that the expression of a-sma was an acquisition through a possible change in 
phenotype of the infused MSCs into a supporting-like tissue within the 
muscle fibres. Despite the large infiltration of these myofibroblast-like cells, 
no apparent muscle impairment was observed in these mice.
The muscle of the ears of these animals were also investigated 
eGFPpos cells were found in 2 out of 13 mice (Figure 10b, 10c). These cells 
exhibited a myofibre morphology and expressed desmin (Figure 10d, 10e) 
and FTM (Figure 10f, 10g) indicating an acquisition of a myofibre-like 
phenotype. Interestingly, these eGFPpos cells formed clusters of 3-5 cells 
each suggesting a possible expansion of donor-derived cells. However, it 
cannot rule out the possibility that eGFP-MSCs fused with existing myofibres. 
The difference observed here among the two skeletal muscle regions is in 
agreement with recent reports indicating significantly different incorporation 
of bone marrow-derived cells among skeletal muscles (Brazelton et al., 
2003).
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Figure 7. In vivo contribution o f eG FP -M S C s into b ronch io lar ep ithe lia l cells  
and hepatocytes
Representative paraffin sections of lung stained either with rabbit immunoglobulins 
(isotype control) (a) or with rabbit anti-pan-CK antibodies (b). Serial sections (c, d) 
show that a group of pan-CK positive cells (red) (c) also stained positive for eGFP  
(d). Representative liver sections with hepatocytes staining positive for eG FP (e, f; 
brown). eG FP expression coincided with albumin (red) giving a brown-purple 
staining (f, small bottom-left figure). Serial paraffin sections from another liver 
showing purple cells with hepatocyte morphology, as a result of co-expression of 
eGFP (red) and CK18 (blue) (h). Isotype control sections shown in g. All sections 
were counterstained with hematoxylin (except for h). Magnifications: x100 (a, b) and 
x400 (c-h).
72
Figure 8. Contribution of eG FP-M SCs into renal epithelial cells
Paraffin-embedded transverse-sections stained with isotype control antibodies show 
no background staining (a). Arrows indicate eGFPP055 cells after staining with rabbit 
anti-eGFP antibody (b, c) co-expressing both lectins Ricinus communis (b, small 
bottom-centre figure; red staining) and Lotus tetragonolobus (d; pink-red staining) 
as shown in serial sections. A frozen section of a kidney demonstrating e G F P ^  
cells by direct visualisation using a fluorescent microscope (e). All sections were 
counterstained with haematoxylin or DAPI e). Magnifications: x200 (a , b , e) and 
x400 (c, d).
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Figure 9. Contribution of eG FP-M SCs into m yofibroblasts in vivo
eGFP positive cells with myofibroblast morphology were located among skeletal 
muscle fibres (a, d; brown). No expression of desmin was observed (b; red staining) 
showing mutual exclusion of expression when double staining for desmin and eGFP  
was performed (c). These same eG FP p0S cells (brown) stained positive for a-sma 
(red) in serial sections (e) resulting in a red-brown color, (f). Sam e section stained 
for both rabbit and mouse immunoglubulins (isotype control) (g). Sections were 
counterstained with haematoxylin. Magnifications: x200 (g) and x400 (a-f).
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Figure 10. Contribution of eG FP-M SCs into m yofibre-like cells in vivo
Representative section of the skin from the ear with myofibres staining positive for 
eGFP (b, c; brown cells). Sam e group of myofibres demonstrating expression of 
desmin (d, e; pink-red staining) and FTM (f, g; red) alone or in combination with an 
eGFP antibody (blue) giving a purple color (e, g). Sections were counterstained with 
haematoxylin (exception for e, g). Magnifications: x200 (a, b, d-e) and x400 (c).
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In conclusion, multiple incorporation events of muMSCs into the 
recipient tissues, following by systemic infusion under substantial tissue 
damage conditions were seen.
3.7 - Discussion
Reports in the literature have so far given a rather confusing concept 
about the in vivo contribution potential of MSCs. Firstly, the majority of the 
studies have used an undefined population of bone marrow cells, making it 
unclear whether these properties are of mesenchymal or haematopoietic 
origin. This is of vital importance as haematopoietic stem cells have initially 
been shown to differentiate into hepatocytes (Lagasse et al., 2000), 
cardiomyocytes (Jackson et al., 2001), Purkinje neurons (Wagers et al.,
2002), renal tubular cells (Kale et al., 2003), or even give rise to multiple 
tissues (Krause et al., 2001) in vivo.
It was very important to define an enriched MSC population before 
addressing the differentiation capacities of muMSCs. This was further 
emphasised by the observation that the adherent fraction of mouse bone 
marrow mononuclear cells contains haematopoietic cells, which can persist 
after several passages (Phinney et al., 1999; Baddoo et al., 2003). This 
finding was confirmed here, and further indicated that a high proportion of 
these contaminating haematopoietic cells have a progenitor/stem cell 
phenotype. By using CD45 and CD11b it was possible to define and sort a 
highly enriched population of muMSCs that were devoid of haematopoietic 
cell contamination and could be efficiently transduced with a lentivirus vector. 
Moreover, the SFFV promoter in this construct retained the reporter gene 
expression through in vitro differentiation of muMSCs, indicating that it is 
functional in different cell lineages and could be utilised in gene therapy 
applications using MSCs.
At the time when these studies were conducted, there were no 
conclusive reports illustrating the in vivo contribution of muMSCs to multiple 
cell-types upon intravenous delivery without severe tissue damage being 
applied to the recipient animals. Only when injury models (Gojo et al., 2003)
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were used and MSCs were locally delivered, the differentiation potentials of 
these cells were observed. Nevertheless, muMSCs can specifically 
differentiate into astrocytes (Kopen et a/.,1999) and type II pneumocytes 
(Ortiz et al., 2003) when injected directly into the spinal cord, brain or 
delivered into the lungs, respectively. Multilineage differentiation of murine 
MSCs has been observed only in the case of murine “Multipotent Adult 
Progenitor Cells” (MAPCs). These cells were shown to differentiate into 
haematopoietic cells in the marrow, blood, spleen, as well as into various 
tissue cell types after i.v administration (Jiang et al., 2002). However, it 
remains to be determined whether MAPCs exist as such in vivo or are a 
consequence of de-differentiation of an MSC-like cell, which might have 
emerged from a specific and selective culture system, giving rise to a unique 
in vitro phenotype.
This study demonstrates that a highly enriched muMSC population 
can be incorporated into several tissues, after systemic infusion into recipient 
animals that only received sub-lethal irradiation. The data indicate that 
infused MSCs can give rise to hepatocytes, renal tubular cells, bronchiolar 
epithelial cells, myofibres and myofibroblast-like cells, although at a low 
frequency. Different explanations could be proposed for the rare occurrence 
of these events. It was chosen to inject MSCs into recipient animals not 
forced to undergo severe organ degeneration and/or repair first. It is possible 
that injured tissues express specific receptors or ligands to facilitate 
trafficking, adhesion and infiltration of MSCs to the site of injury. Indeed, a 
recent report showed that muMSCs could differentiate into type II 
pneumocytes after systemic infusion in bleomycin-treated mice (Ortiz et al.,
2003). The difference in the type of lung cells that MSCs differentiated into 
compared with this study, can be explained either by the importance of 
specific tissue damage in promoting/enhancing this type of phenomena, or 
by the different experimental design used here. Although sub-lethal 
irradiation could incur some damage to the lungs, the physical retention of 
MSCs in this organ might have resulted from the large number of cells 
transplanted, or the fact that they weakly express appropriate adhesion 
molecules. As a consequence, this retention may have drastically reduced 
the number of potential MSCs capable of homing to other organs. These
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findings are in accordance with previous reports (Gao et al., 2001; Barbash 
etal., 2003). However, there are no reports on the potential detrimental effect 
that this retention of MSCs in the lung may cause on lung function. Thus, it 
can be suggested that systemic infusion might not be the best delivery route 
for this type of stem cell. In order to drive or enhance the homing and 
differentiation ability of the transplanted MSCs for tissue repair, specific or 
selective pressure may be required.
Again, the lack or weak expression of integrins and other adhesion 
molecules that play a vital role in cell migration and/or attachment to different 
tissues may also account for the inability of muMSCs to home back to the 
bone marrow. As reported recently, this loss and/or change in 
homing/attachment capacity of these cells could be due to the culture 
conditions used (Rombouts et al., 2003). Based on this fact, better 
understanding of the signalling mechanisms that attract bone marrow cells to 
specific tissues will be necessary in order to enhance the prospects of 
systemic delivery of MSCs as a therapeutic method for tissue repair. Local 
infusion of MSCs to a tissue of interest might be an attractive alternative 
route of delivery.
Another possible explanation for the low frequency of the 
differentiation events seen here is that the MSC compartment is very 
heterogeneous and although an enriched MSC population was used, this 
may not have included the most primitive and possibly most multipotent cells. 
As described in the following chapters, MSCs contain a minor population of 
quiescent cells sharing some MAPC features (Jiang et al., 2002). 
Interestingly, despite the high transduction efficiency obtained with the 
lentivirus vector, it was observed that the majority of this subpopulation of 
cells lay in the untransduced fraction (<2%). Therefore, cells with higher 
differentiation capacity might have unexpectedly been excluded from these 
experiments.
Finally, it is still unclear what mechanism is responsible for the 
observed differentiation phenomena shown in this study. Recent reports on 
the differentiation capacity of haematopoietic cells have identified fusion as 
the primary mechanism responsible for the observed phenomena (Terada et 
al., 2002; Ying et al., 2002; Alvarez-Dolado et al., 2003; Wang et al., 2003;
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Camargo et al., 2004; Willenbring et al., 2004). Although there are other 
mechanisms apart from fusion that have been shown to occur (Harris et al., 
2004; Jang et al., 2004). The contribution of MSCs into different cell types 
reported here could have arisen from trans-differentiation, de-differentiation, 
fusion with resident cells or even a combination of these possible 
mechanisms. Although fusion is not the mechanism responsible for the in 
vitro differentiation capacity of muMSCs described here, we could not rule it 
out as a phenomenon occurring in vivo and in vitro, as recently described for 
haematopoietic cells (Alvarez-Dolado et al., 2003). It is possible that eGFP- 
MSCs that have been incorporated into the liver and the skin (myofibres) 
could have resulted from fusion. The main aim of this study was to address 
the “natural” distribution of MSCs into different organs after systemic delivery, 
and possible in vivo contribution capacity of these cells. Due to the 
experimental design of this study it was unable to address the mechanism of 
these differentiation events.
In summary, a defined and highly enriched muMSC population was 
capable of incorporating into various cell-types when administered 
systemically under minimal damage conditions. Despite the low frequency of 
such phenomena, this observation demonstrates for the first time that 
muMSCs have multipotent capacities in vivo.
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Chapter 4 - Newly identified SSEA-1pos cells as
the most primitive fraction of mu MSC 
compartment
4.1 - Brief introduction and description of the study
Since the first description of MSC in early 70’s, researchers have 
failed to isolate the most primitive cell-type from the bulk cultures of 
mesenchymal cells. Through indirect methods and accumulative 
observations throughout the years, it has created in the scientific community 
the notion/speculation that ex-vivo expanded MSCs are very heterogeneous 
and composed mainly by mesenchymal cells (without any stem cell property) 
and some progenitors/stem cells. The lack of an appropriate way to isolate 
and expand the “true” mesenchymal stem cell from a very heterogeneous 
population had led to much discouraging data concerning their in vivo 
function because in most (if not all) of these studies undefined bulk cultures 
of MSC were used. Indeed, results just presented in chapter-3 confirmed this 
speculation. Firstly, it was observed that upon in vitro stimulation only a 
fraction of the cells was capable of differentiating into its respective lineage. 
Moreover, the in vivo contribution capacity of the cells was somewhat rare. 
This is also the reason why it has been called “enriched or bulk MSC 
cultures” instead of “MSC cultures” throughout this manuscript.
In fact, as described in the general introduction section, much of the 
mesenchymal stem cell biology remains elusive, especially its hierarchical 
organisation. Although some data suggest that MSCs are composed of 
different subpopulations of progenitors or cells that are prompted to 
differentiate preferentially into one or few different cell-types in vitro (Bianco 
et al., 2001; Gronthos et al., 1999 and 2003; Muraglia et al., 2000; Zannettino 
et al., 2003; Wistel-Gendebien et al., 2003), there is no defined hierarchy 
proposed yet, especially at the most primitive level. Several groups have 
reported the use of different cell surface antigens to isolate/enrich different
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MSC-progenitors (Gronthos et al., 1999 and 2003; Wistel-Gendebien et al.,
2003). However, there is no defined universal stem/progenitor cell marker 
yet, which could be used to isolate/enrich the putative most primitive MSC 
population capable of highly differentiating into different cell-types both In 
vitro and in vivo, ultimately demonstrating the true multipotency of MSCs.
Recently, murine multipotential adult progenitor cells (Jiang et al., 
2002) with features of embryonic stem cells have been described. In fact 
when injected into early blastocysts, a single MAPC can contribute to most, if 
not all, somatic cell types. Similarly, when using culture conditions mimicking 
the microenvironment of the marrow niche it is possible to isolate multipotent 
cells from human bone marrow (D’lppolito et al., 2004). Nevertheless, like 
MAPCs, no prospective isolation of these multipotent cells exists yet, making 
their existence as such in vivo still uncertain.
As such, there was a necessity to identify (or attempt to) the putative 
stem cell within the bulk MSC cultures. Based on studies performed by D. 
Prockop’s and C. Verfaillie’s groups a new subpopulation of MSCs was 
identified. These cells have a peculiar phenotype by expressing the SSEA-1 
antigen. Optimisation of protocols for SSEA-1pos cell isolation from bulk 
cultures was first conducted. Then, SSEA-1pos-MSCs were 
immunophenotyped and differentiation capacity studies were carried out. 
Some molecular phenotyping and in situ localisation of this newly identified 
cell-type directly in the bone marrow was also performed.
4.2 - muMSCs differentiate into cell-types of the three- 
germline layers in vitro
In order to minimize potential culture artefacts that could alter any cell 
fate, a simple method to enrich and expand muMSC based on their ability to 
adhere to plastic followed by negative selection using CD45 and CD11b was 
performed as described previously. After enrichment, the in vitro 
differentiation capacities of MSCs were verified. Similarly to eGFP-MSCs, un­
transduced cells upon appropriate culture conditions were able to give rise to
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adipocytes, osteoblasts, myoblasts and astrocyte/neuronal-like cells 
determined by immunocytochemistry staining (Figure 11). Furthermore 
under endothelial culture conditions some of the MSCs acquired the 
expression of vWF and CD31 (data not shown). Similarly, under hepatocyte 
differentiation conditions albumin, HNF (Hepatocyte Nuclear Factor), and 
CK-18 positive cells could also be detected (Figure 11). Therefore, bulk 
cultures of muMSCs were capable of differentiating into different cell-types of 
the three-germline layers in vitro. As mentioned above, during the course of 
the experiments, it was observed that upon MSC differentiation down a 
specific pathway, only a fraction of the cells were capable of doing so. With 
the exception of astrocyte/neuronal and endothelial differentiation, where a 
higher proportion of cells expressed the respective lineage-specific antigens, 
in all other in vitro conditions only clusters of differentiated cells could be 
observed. Data shown were further supported by FACS analysis performed 
on the same or other lineage-specific antigens used in immunocytochemistry 
studies (see below).
4.3 - Identification of SSEA-1pos cells in the muMSCs 
compartment
The in vitro results are in accordance with the concept/speculation that 
the MSC compartment is heterogeneous and composed of different types of 
stem/progenitor cells, which are capable of differentiating into one or a few 
lineages under the appropriate in vitro conditions (Bianco et al., 2001; Deans 
and Moseley, 2000; Gronthos et al., 1999 and 2003; Javazon et al., 2001; 
Muraglia etal., 2000; Zannettino et al., 2003; Wistel-Gendebien etal., 2003).
Firstly, immunophenotyping studies were conducted by using several 
markers reported to be expressed on MSCs from different species (Deans 
and Moseley, 2000; Javazon et al., 2001). As shown by others (Colter et al., 
2000; Deans and Moseley, 2000; Muraglia et al., 2000), no subpopulation 
could be defined by using such antigens (Figure 12).
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Figure 11. In vitro differentiation of muMSCs into different cell-types of the 
three-germ line layers
Representative pictures from several different experiments (n=3 to 6). Unstimulated 
M SCs were viewed under light microscope (a ). A fter 14 days of adipogenic 
induction, cells were fixed and stained with Oil Red O (b, c; b-was viewed under 
black-phase contrast). O steogenic potential w as determ ined by alkaline- 
phosphatase staining (d, e). An area of osteoblast-like cluster formation is also 
shown (e). Staining for specific antigens for myogenic (f-h), astrocyte/neuronal (i-l), 
hepatocyte (m-r) and endothelia l (s , t )  lineages  w ere  perform ed by 
immunofluorescence. Myogenic differentiation was confirmed with single staining for 
dystrophin-TRITC (g) and desmin-Cy3 (h). Specific staining for astrocyte/neuronal 
antigens was performed with N euN -FITC  (j), G FA P-C y3 (k) and Tau-TR ITC  (I). 
Hepatocyte and endothelial-like cells were confirmed with staining for CK18-FITC  
(n, r), albumin-FITC (o, q), H N F-TR ITC  (p, q, r) and vW F-FITC  (t) respectively. 
Cells were counter-stained either with haematoxylin (a -e ) or DAPI (f-k, m -o, s). 
Respective isotype controls conjugated with F ITC  and C y3 /TR ITC  were also 
performed for each individual lineage (f, i, m, s). Original magnifications of X100 (a, 
b), X200 (d, f-m, o-q, s, t), X400 (c, e, n, r).
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Figure 12. Im m unophenotype profile o f enriched MSC cultures
Examples of FACS histograms showing that enriched MSCs cultures after depletion 
of C D 45/C D 11bpos cells no longer contain haematopoietic contaminants (C D 45/ 
Ter119 /C D 11b /C D 117 expressing cells). Moreover, using different markers that 
have been used to define mouse, rat and human MSCs, such as CD90, CD105, 
CD34, CD44, CD73 and Sca-1, failed to reveal any distinct subpopulation within the 
bulk cultures. All FACS plots shown: grey and white areas are the isotype control 
and specific antibody staining respectively.
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Therefore, the existence of a primitive subpopulation previously reported for 
human and rat MSCs (Colter et a/., 2000 and 2001; Javazon et al., 2001) 
was investigated. The small and quiescent subpopulation, referred to as RS1 
cells, displays a phenotype (e.g. expressing CD71; Trk or NGF, nerve growth 
factor; KDR or Flk-1 or VEGF-R2, vascular endothelial growth factor 
receptor-2), which is different from the most abundant, fast growing and 
committed precursors (Colter et al., 2000). However, the full differentiation 
capacity of these cells into the three-germline layers, both in vitro and in vivo, 
was not demonstrated. Therefore, the presence of such a subpopulation in 
bulk cultures of muMSCs by using KDR and Trk as markers was analysed. It 
was observed that muMSCs expressed these antigens (Figure 13a-13c) and 
Trk and KDR expressing cells comprised between 0.5-1.2% and 0.4-0.8% of 
muMSCs (from 4 different extractions), respectively. Interestingly, all KDR 
positive cells co-expressed Trk (Figure 13c) and these cells were small and 
agranular (with low side- and forward-scatter by flow-cytometry analysis). 
Thus, these data indicate that muMSCs do effectively contain RS1 cells.
Bulk cultures of muMSCs were then analysed for the presence of 
SSEA-1 expressing cells, an antigen described to be expressed on MAPCs. 
FACS analysis revealed the existence of a subpopulation expressing SSEA- 
1 in MSCs cultures (Figure 13d). The SSEA-1 positive subpopulation, 
comprised 0.45-0.97% of all muMSCs (n=4) and, interestingly, this proportion 
remained constant throughout further passages (data not shown). Further 
analysis of muMSCs also revealed that the majority of the quiescent cells (in 
confluent cultures) residing at GO were composed mainly of SSEA-1pos cells 
(Figure 13f, 13g).
These findings led to speculation that SSEA-1 pos-MSCs might be 
similar to, or at least part of, the RS1 subpopulation. SSEA-1 pos-MSC 
population is still heterogeneous and it does not only include the RS1 cells 
(that are KDRpos and Trkpos) but other cell-types as well. The SSEA- 
1pos/KDRpos/Trkpos fraction comprised around 70-80% of the SSEA-1pos cells, 
while the second major fraction was negative for KDR and Trk (Figure 13e) 
and comprised <25% (n=4) of this subpopulation. A third small fraction could 
be occasionally identified, expressing only Trk.
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Figure 13. Revealing the hierarchical organization of muMSC
Representative flow cytometry plots of MSCs from passage 5. FACS analysis 
showing that MSCs contain RS1-like cells expressing KDR (a, c ) and Trk (b, c). 
SSEA-1 is expressed on MSCs (d) and this population is still heterogeneous for 
KDR and Trk expression (e). Hst/PY staining (f) reveals that the quiescent (GO) 
MSC subpopulation is highly enriched for SSEA-1 expressing cells (g; grey and 
white areas are the isotype control and SSEA-1 antibodies staining respectively). 
Insert FACS plots represent isotype control staining.
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4.4 - SSEA-1 pos-MSCs are at the apex of the muMSCs 
hierarchy and multipotent in vitro
All the data presented support the hypothesis that SSEA-1pos cells are 
at the apex of the muMSCs hierarchy. In order to test this, both SSEA-1 
positive (>90% purity) and negative (>98% purity) fractions were sorted from 
enriched muMSCs cultures and placed back in culture. Subsequent analysis 
of these cells for SSEA-1 expression was performed when cultures were 
approximately half or almost confluent. Results clearly showed that after 
culture the SSEA-1pos subpopulation gave rise to the negative fraction 
(Figure 14a, 14b) whereas the reverse situation was not seen (Figure 14c). 
This strongly suggests a differentiation and/or maturation from SSEA-1pos to 
SSEA-1neg phenotype.
Additional purification of SSEA-1pos cells clearly showed that SSEA- 
1pos/KDRposdid not give rise to SSEA-1 pos/KDRneg cells (Figure 14d), but only 
to SSEA-1 ne9/KDRneg cells. Similarly, loss of SSEA-1 was observed when 
SSEA-1 pos/KDRneg cells were placed in culture. In this case, however, a small 
proportion of cells retained their original phenotype when cultures had 
reached confluence (Figure 14e). Additionally, a very small but distinctive 
fraction of SSEA-1 pos/KDRpos cells was also found suggesting that SSEA- 
1pos/KDRneg cells could give rise to SSEA-1 pos/KDRpos cells (RS1 cells).
To further examine that SSEA-1 pos-MSCs are the most primitive cells, 
the in vitro differentiation capacities of these cells were determined. Different 
methods were applied for isolating these rare cells from bulk cultures. Based 
on the fact they usually comprise <1% of the whole MSC fraction, direct 
sorting resulted in a very poor viability of the cells due to long sorting hours 
required to obtain reasonable amounts of cells for subsequent experiments. 
Immunolabelling followed by separation using Dynabeads™, StemSep™ and 
MACS™ cell purification systems were tested and two rounds of column 
separations by the MACS system gave the best purity, viability and yield of 
the cells. As such, all subsequent isolations of SSEA-1pos cells were 
performed using MACS.
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Figure 14. SSEA-1pos-MSC at the top of murine MSC hierarchy
Hierarchical studies performed with different subpopulations of M SCs. Purified 
SSEA-1 p08 (a -  upper left plot) and S SEA -1neg (a -  bottom left plot) cells were plated 
and analysed few days later. Expression of SSEA-1 from the S S E A -1pos cultures 
after attaining half confluency (a -  right plot, n=2) and almost confluency (b, n=3). 
Cells from the negative fraction were also stained for the sam e antigen when  
cultures attained half confluency (c, n=3). Similar studies were also performed with 
the two main subpopulations of S S E A -1905 cells. SSEA-1 pos/KDRne9 (d, n=3) and 
SSEA-1 pos/KDRpo8 (e, n=7) fractions were re-analysed for the expression of the 
same antigens when cultures attained almost confluency.
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Enriched SSEA-1 pos-MSCs (-60-70% purity) were compared to 
unfractionated muMSCs. FACS results clearly showed higher expression of 
different antigens for each specific lineage when the enriched SSEA-1pos 
fraction was used, compared to bulk cultures (Figure 15). The expression of 
these antigens was not detected on unstimulated cells (Figure 15). For the 
neuroectodermal lineage, all the studies were focussed on the astrocytic 
lineage since most of cells acquired GFAP and GLAST, although some Tau 
and NeuN positive cells were also detected in the induced cultures.
Based on the fact that SSEA-1pos cells comprise a very small fraction 
from the bulk MSC cultures and they are very difficult to isolate, western-blot 
analysis for the expression of all the specific antigens was not possible. 
Thus, FACS analysis was used instead. To validate the FACS data, the 
specificity of all the antibodies was confirmed by western-blot first and this 
was performed using bulk MSC cultures (before and after in vitro 
stimulation). Moreover, appropriate antibody-isotype controls were also used, 
which were selected based on the closest match between their respective 
M.F.I (mean fluorescent intensity) values with the ones obtained from an 
antibody which recognises an antigen that is absent in the cells (e.g. anti- 
eGFP, since the cells were not tagged with eGFP).
4.5 - SSEA-1 pos-MSCs share similarities with MAPCs and exist 
in vivo
This higher differentiation capacity of SSEA-1pos cells led to the 
investigation of whether SSEA-1pos cells share similar features with MAPCs, 
as this is the only cell-type known to have high differentiation capacities. 
Therefore SSEA-1pos and SSEA-1neg cells were placed in MAPC culture 
conditions and allowed to expand for -10 doublings (n=3) before they were 
further analysed for the expression of antigens, previously used to 
characterise MAPCs. Both positive and negative cells were capable of 
expanding under those culture conditions but only the positive fraction
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Figure 15. C om parative s tudy  of the in vitro  d ifferentiation  capacities o f un­
fractionated MCSc and enriched SSEA-1 pos-MSC populations
FACS histograms show levels of expression of specific antigens for M SC  
differentiation into osteogenic (osteocalcin and Bone Sialoprotein II, BSP II), 
myogenic (dystrophin and desmin), astrocyte (GFAP, GLAST), hepatocyte (albumin 
and HNF), and endothelial (extracellular CD31 and vW F) lineages. Grey and white 
areas are the isotype control and specific antibody staining respectively. The  
numbers shown indicate the levels of expression for each antigen that were  
calculated using the M.F.I (mean fluorescent intensity) values obtained from each 
specific staining over the values from their respective isotype controls.
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maintained the expression of SSEA-1, KDR and Trk (Figure 16a). Results 
showed a slight overall down-regulation of these three antigens on the 
positive subpopulation, as well as for MHC-I and CD44 (Figure 16a). The 
levels of expression of these same antigens were maintained in further cell 
doublings under MAPC culture conditions (data not shown). Additionally, 
expression of Rex-1 and Nanog were also detected in the highly purified 
SSEA-1pos cells (-90% purity), especially when they had been expanded 
under MAPC culture conditions (Figure 16b). The SSEA-1ne9 MSC fraction 
on the other hand, was negative for these embryonic antigens before and 
after culture in MAPC culture conditions, even after expanding for more than 
30 doublings (data not shown). Quantitative RT-PCR was not performed on 
these cells, as QRT-PCR data does not differentiate between high levels of 
expression in a few cells versus uniform expression of a marker in all of the 
cells. Considering the heterogeneous nature of the culture, it is possible that 
a subset of SSEA-1pos cells could have high levels of ES marker expression 
that may represent only a fraction of the total SSEA-1pos fraction.
Despite being able to isolate and identify a subpopulation of cells in 
bulk MSC cultures with features similar to those of MAPCs, the question of 
their true existence directly from the bone marrow remained. Therefore, in 
order to investigate their presence in the bone marrow, searching for the 
presence of SSEA-1 expressing cells in the Linneg/CD45neg/CD31ne9 fraction 
(Anjos-Afonso et al., 2004) of bone marrow cells was performed. As such, an 
SSEA-1pos population in the MSC compartment (R1 from Figure 17a) was 
identified. This population comprised -0.04% of the Linneg/CD45neg/CD31neg 
fraction in an adult mouse (aged >12 weeks old). Interestingly, the same 
population in 2 weeks old mice was 30-fold enriched, with SSEA-1pos cells 
reaching a frequency of 1.5%. This SSEA-1pos cell population decreased with 
age (Figure 17b) showing a variation during mouse ontogeny. Also, these 
SSEA-1pos cells expressed Sca-1 (Figure 17a). Additionally, using 
multicolour immunofluorescence staining it was possible to identify the in situ 
bone marrow location of these cells, which is in close vicinity to 
CD45/CD11b/TER119/CD31pos cells and slightly enriched below the 
endochondral-bone region in a developing bone (Figure 19a-g).
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Figure 16. SSEA-1 pos-MSCs share s im ilarities w ith MAPCs
(a) Both FACS sorted S S E A -1pos and S S E A -1neg cells were expanded for -1 0  
doublings in MAPC culture system and then analysed for characteristic surface 
antigens (n=3) previously used to define M APCs. As a comparison, the same 
surface antigens were used to immunophenotype these two fractions before 
expansion (day 0). Flow histograms: grey and white areas represent isotype control 
and specific antibody staining respectively, (b) Expression of Oct-3/4, Rex-1 and 
Nanog by R T -P C R  on different M SC  subpopulations; representative gel 
electrophoresis with p-actin as the internal PCR control; lane 1- ES cells, lane 2- 
water, lane 3- SSEA-1neg -M SCs, lane 4- MACS enriched SSEA-1 pos-M SCs, lane 5- 
FACS purified and expanded SSEA-1 neg-M SCs in MAPC conditions, lane 6- FACS  
purified and expanded SSEA-1 ^ -M S C s  in MAPC conditions.
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Figure 17. SSEA-1 pos-MSCs exist in vivo
Identification of SSEA-1 expressing cells directly from BMMNCs. Lineage depleted  
BM M NCs were stained with L in /C D 45/C D 31, SSEA-1 and Sca-1. Representative  
FACS staining performed on cells derived from 2 weeks old mice. The negative 
fraction for the expression of Lin/CD45/CD31 (a) was gated (R1) and plotted for the 
expression of SSEA-1 and Sca-1 (a). Variation of the frequency of the S SEA -1p0S 
cells during the mouse ontogeny (b). The frequency was calculated by multiplying 
the percentage of MSCs in BM M NCs (R 1) with that of SSEA-1pos cells in the M SC  
population (R2) obtained for each group of mice. The analysis was performed on 
pooled samples of BMMNCs from 8 (2 weeks old), 10 (4 weeks old), 6 (6 weeks old) 
and 3 (>12 weeks old; n=2) mice respectively for each group.
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Figure 18. In situ identification of SSEA-1908 cells
Bone sections were stained either with mouse IgM immunoglobulins (isotype 
control) (a, b) or with SSEA-1 antibody (d-g). Serial sections (a, d) show specific 
staining for SSEA-1 (green cells indicated by the arrows) in the bone marrow. 
SSEA-1 ^  cells can be found throughout the marrow but they are slightly enriched 
below the endochondral-bone area (highlighted area of d) in a developing bone. 
Representative bone sections with marrow stained positive for 
CD45/CD11b/Ter119/CD31 (c, f, g, red). SSEA-1pos cells are located in close 
vicinity to CD45/CD11b/Ter119/CD31p0S cells but they did not stain positively for 
either hematopoietic or endothelial antigens. As an example, a SSEA-1 expressing 
cell (green cell indicated by the arrow, f) shows no expression of 
CD45/CD11b/Ter119/CD31. All sections were counterstained with DAPI. 
Magnifications: x100 (a, c) x200 (b, d), x400 (f) and x1000 (e, g).
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Although the above results clearly demonstrate that SSEA-1pos can 
give rise to SSEA-1neg cells and are therefore suggesting that SSEA-1 
expressing cells are the most primitive cell-type, this hypothesis is based on 
the assumption that these two groups of cells are developmentally related. It 
is very possible that some or even most of the non SSEA-1 expressing cells 
in the bulk MSC cultures have derived from a different multipotent 
stem/progenitor that lacks SSEA-1 expression. As such, it was tested 
whether SSEA-1neg cells directly isolated from the bone marrow could 
establish MSC cultures. For this experiment, both SSEA-1pos and SSEA-1neg 
fractions from the Lin/CD45/CD31neg fraction were purified directly from the 
bone marrow by FACS and cultured independently (F igure 19a). Since the 
initiation of muMSC cultures is dependent on the presence of haematopoietic 
cells, Lin/CD45/CD31pos cells were added to each purified SSEA-1 fraction. 
The number of cells used for each fraction was proportional to their 
frequency in the bone marrow. When purified SSEA-1pos cells were used, 
although no delineate CFU-F colonies were formed and the time required for 
the cells to reach confluency was longer, MSC cultures were obtained in all 
of the attempts tested (3 out of 3 independent cultures; Figure 19b). This is 
probably due to the significant lower number of adherent haematopoietic 
cells found in these cultures in comparison to the conventional method of 
initiating MSC cultures (F igure 19c). However, no MSC cultures were 
obtained when SSEA-1neg cells were used (0 out of 5 independent cultures), 
demonstrating that establishing muMSC cultures is dependent on the 
presence of SSEA-1 expressing cells. Also, when BMMNCs from old mice 
were used (> 15 weeks old NOD/SCIDs; as less SSEA-1pos cells are present) 
the adherent fractions did not go beyond P2, as most of the cultures did not 
harbour a significant amount of CD45/CD11 bneg cells (Figure 19d).
4.6 - Discussion
In this chapter is reported the identification, prospective isolation from 
cultures and characterisation of a new subpopulation of mouse MSCs, based 
on the expression of the SSEA-1. These cells can be found not only after in
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vitro culture but also directly from mouse bone marrow, therefore proving the 
existence of a subpopulation of MSCs with some embryonic features that 
reside in adult life. Although the in situ localisation of these cells in the bone 
marrow was determined, due to their rarity and weak avidity of the SSEA-1 
antibody, the exact distribution of these primitive cells in the marrow could be 
different from the data presented. A better marker such as Oct-4, using Oct- 
4-eGFP mice, might be very useful to further determine the distribution of 
these cells in vivo.
Despite the heterogeneity of the SSEA-1pos fraction, the hierarchical 
studies performed strongly suggest that this subpopulation is the founder of 
MSC compartment, thus providing the evidence for a hierarchical 
organisation. Although the relationship and differences between the two main 
subpopulations of SSEA-1pos cells (SSEA-1pos/KDRpos and SSEA- 
1 p°s/KDRne9) were not completely explored, SSEA-1 seems to mark the most 
primitive fraction described so far. Based on the data shown and personal 
observations made, it appears that KDR and Trk expressions (the acquisition 
of high expression) seen were due to ex-vivo expansion conditions applied. 
Firstly, KDR and Trk expressions within the mesenchymal compartment 
directly from bone marrow (defined as Lin/CD45/CD31ne9) and in early 
adherent cultures were dim and the two subpopulations could not be 
delineated as clearly as in later passages when cultures were already devoid 
of haematopoietic contaminants. Secondly, when isolating SSEA-1pos in 
general from bulk cultures (which includes the two main fractions) and 
expanded in the MAPC culture system, the two sub-fractions seem to 
converge to a common phenotype KDR/Trkdimpos.
All the observations made suggest that ex-vivo expansion using 
conventional mesenchymal medium might have driven the cells to a possible 
more mature phenotype or one with more confined differentiation potentials.
Nevertheless, it does not mean that it is less important to understand 
the biology of each sub-fraction. On the contrary, defining expansion 
conditions for the maintenance of self-renewal and properties for SSEA- 
1pos/KDRpos may be very interesting, because this sub-fraction could be more 
useful for in vivo vascular and nervous system repair studies, as they already
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express the appropriate receptors they could be more prone to differentiate 
into endothelial and astrocyte/neuronal-like cells.
Finally, it was also demonstrated that SSEA-1 pos-MSCs have a much 
higher capacity to differentiate into several cell-types of the three germline- 
layers than their negative counterparts in vitro and also required to initiate 
MSC cultures. Thus, all the data presented strongly suggest that SSEA-1pos 
cells are at the apex of the murine mesenchymal stem cell compartment 
(Figure 20).
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Figure 19: SSEA-1pos cells are required to establish muMSC cultures
(a) Both SSEA-I^ (R1) and SSEA-1neg (R2) fractions were purified from lineage 
depleted BMMNCs and cultured independently in the presence of Lin/CD45/CD31pos 
(R3) cells, (b) Only when the SSEA-1pos fraction was used, were bulk MSC cultures 
obtained (n=3). Representative FACS plot of P1 adherent culture initiated by SSEA- 
'\'pos cells showing little haematopoietic contamination (CD45/CD11bpos cells) in 
comparison to P1 adherent culture initiated with un-sorted BMMNCs (c). (d) When 
older mice were used (>15 weeks old) adherent fractions could not be passaged 
beyond P2 due to the lack of mesenchymal cells in culture (CD45/CD11bneg subset).
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Figure 20: Hierarchical model proposed for the primitive bone marrow derived 
muMSC compartment.
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Chapter 5 - In vitro and in vitro multipotencv of
clonallv derived SSEA-1 pos-MSCs
5.1 - Brief introduction and description of the study
In order to fit into the conventional definition of a stem cell (which 
should be clonally self-renewing and multipotent) a single stem cell must be 
isolated and demonstrate its multipotentiality.
From the results presented so far, it is still unclear whether the high 
multilineage differentiation potential seen was uniform for all SSEA-1pos cells 
or restricted to different SSEA-1pos fractions with more confined differentiation 
capacities. Also, it is unclear whether the expression of Oct-4, Nanog and 
Rex-1 is homogeneous for all the cells.
So far all the data presented were conducted using either enriched or 
purified SSEA-1pos fractions. Indeed, as shown above, the SSEA-1pos cells 
are still heterogeneous in regards to KDR and/or Trk expression. As such, it 
was attemped to isolate and expand single SSEA-1pos cell-derived 
populations. Many attempts were made and finally three SSEA-1pos clones 
were obtained. These clones were characterised at the cellular and 
molecular level in a similar fashion as previously demonstrated in Chapter-4. 
Due to the high maintenance required for expanding these cells 
(seeding/maintenance at very low density and constant replenishment of 
fresh cytokines), one clone (clone-3) was randomly selected for a more 
detailed description. The multilineage differentiation into the three germline- 
layers in vitro was tested and the functional aspects of the different cell 
derivates were also assayed. Finally, in order to prove that this newly 
identified cell-type had multipotent features in vivo, transplantation studies 
were performed and different tissues were screened for the possible 
contribution of these SSEA-1pos cells into different cell-types.
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5.2 - Characterisation of clonally derived SSEA-1pos cells
Due to the peculiar nature of murine mesenchymal cells it was not 
possible to isolate/expand any mesenchymal cell-type directly from the bone 
marrow (cells defined as Lin/CD45/CD31neg). Indeed, for the isolation of 
muMSC in general, it seems that certain factors and/or direct contact with 
haematopoietic cells is essential to establish early cultures. Establishing 
cultures of these cells directly after isolation from the bone marrow was 
completely unsuccessful despite many attempts. Future studies are required 
to determine why direct isolation of MSC (or SSEA-1pos cells) from murine 
bone marrow was not achievable. As such, a single SSEA-1pos cell was 
sorted from the earliest adherent cultures to minimize the ex-vivo expansion 
time required (Figure 21a) and expanded under MAPC culture system, 
shown previously to be able to maintain the phenotype and features of 
SSEA-1pos cells. Under this stringent culture system, three SSEA-1pos clones 
were obtained. Preliminary studies using low number of cell doublings 
revealed that all three clones showed similar cell expansion kinetics, 
phenotype (Figure 21b, 21c) and in vitro differentiation capacities (data not 
shown). Thus, clone-3 was randomly selected for more detailed 
characterisation. Clone-3 cells were able to expand linearly over time (Figure 
21b) with the maintenance of expression of SSEA-1 (high expression), MHC- 
I and CD44 and low levels of KDR and Trk at different time points (Figure 
21c), suggesting that these cells have self-renewal features in vitro. 
Interestingly, high levels of expression of Oct-3/4, Rex-1 and Nanog at the 
RNA level were detected (Figure 22).
Thus, it was investigated whether this high RNA expression of these 
embryonic transcription factors could also be reflected at the protein level. It 
was observed that the expression of such factors at the protein level was not 
only maintained throughout the expansion period but also comparable to ES 
cells (determined by FACS analysis, Figure 23a). To support the FACS data 
nuclear localisation was performed using immunocytochemistry staining 
(Figure 23b). Also, the SSEA-1neg fraction did not stain for the antibodies 
used, further confirming the specificity of the results presented.
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Figure 21. Isolation and characterisation of clonally derived SSEA-1 pos-MSCs
A single SSEA-1pos cell was sorted from adherent cultures from passage 1, which is 
composed mainly of C D 45/C D 11bpos cells (a), (b) Representative graph of growth 
kinetics from the three surviving clones, (c) Expressions of SSEA -1, KDR, Trk, 
M HC-I, C D 44 on different clonally derived populations and the m aintenance of 
phenotype of clone-3 cells throughout time.
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Figure 22. Clonally derived SSEA-1pos cells express high levels of ES 
transcriptional factors at RNA level
(a) Real-time analysis of Nanog, Rex-1 and Oct-3/4 expressions in ES cells (green 
lines and bars), clone-3 cells at 30 doublings (yellow lines and bars) and at 45  
doublings (blue lines and bars) respectively. Relative mRNA expressions (AACT) 
were obtained after normalising the CT values from each gene with the internal PCR  
control (p-actin) then using the ACT values from ES cells as reference. All 
quantitative results shown are the mean values, each one performed in triplicate. As 
an example, amplification plot of Nanog (b) and its respective dissociation curve (c), 
to verify the specificity of the product (in this case the specific TM is 84.1 °C), are 
also shown. NTC: non-template control.
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5.3 - Clonally derived SSEA-1pos cells are multipotent in vitro
Similarly to what has been shown in Chapter-4, clone-3 SSEA-1pos 
cells were able to give rise to osteoblast/osteocyte, endothelial-, hepatocyte-, 
astrocyte/neuronal-like cells, which were confirmed by detecting specific 
antigen expressions for each lineage using immunostaining (Figure 24), 
FACS analysis (Figure 25) and RT-PCR (data not shown). The acquisition of 
specific-lineage antigens upon stimulation was high in the clonally derived 
population. Also, differentiated cells were able to acquire more mature 
phenotypes (in comparison to bulk MSC cultures) with acquisition of 
osteocalcin (which indicates the presence of osteocytes; Figure 24) for the 
osteogenic lineage and for the neuroectoderm lineage we could detect some 
occasional clusters of GABA or DOPA (Figure 24) positive cells. 
Furthermore, differentiated cells also acquired functional features. 
Osteoblasts/osteocytes derived from clone-3 cells showed high levels of 
alkaline phosphatase activity (Figure 26a) and were able to deposit calcium 
(Figure 26b).
Four different assays were used to determine the functional aspects of 
hepatocyte-like cells derived from the clone-3 cells. Initially, assays were 
used for the determination of levels of albumin and urea. However, the 
commercial available kits (mouse specific albumin ELISA kit and Urea 
calometric kit) were not sensitive enough to correctly quantify the low 
amounts of albumin and urea, respectively, produced by the cells. 
Hepatocyte-like cells were shown to deposit glycogen and to have 
cytochrome P450 activity instead. Indeed, differentiated cells were able to 
deposit a considerable amount of glycogen, which was revealed by the PAS 
assay (Figure 27a), and showed cytochrome P450 activity even before 
induction with phenobarbital (Figure 27b).
After stimulation with VEGF, clone-3 cells did not only acquire 
expression of CD31 and Tie-2 but also Weibel-Palade bodies containing 
vWF. One characteristic of an endothelial cell is that they can take up LDL 
(Steinberg et al., 1985) and therefore this was tested.
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Figure 23. Clonally derived SSEA-1pos cells express high levels of ES 
transcriptional factors at protein level
(a) Flow histograms showing levels of expression of Oct-4, Nanog and Rex-1 in the 
clonally derived population. SSEA-1 ne9-M SCs and ES cells were used as negative 
and positive controls respectively. For all flow histograms: grey and white areas are 
the isotype control and specific antibody staining respectively, (b) Multicolour 
immunostaining performed on clone-3 cells from 45 doublings showing that Nanog 
(red; Alexa594) and Rex-1 (red; Alexa594) are more homogeneously expressed in 
the nucleus, whereas Oct-4 (green, A lexa488) expression seem s to be more 
concentrated in some areas surrounding the nucleus. An example of SSEA-1 (red; 
TexasRed) with Oct-4 staining is also shown. Appropriate rabbit IgGs, mouse IgM 
and mouse lgG1 isotype controls were also used. Magnifications: X 200 (first top 
three pictures of b) and X400 (remaining pictures of b).
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Figure 24. Multipotency of clonally derived SSEA-1po# cells determined by 
immunocytochemistry analysis
Representative pictures from two independent in vitro differentiation assays  
performed using clone-3 derived cells. Osteogenic potential was determined using 
alkaline phosphatase activity (red staining) and staining with osteocalcin-Alexa594 
and BSP ll-FITC. Endothelial differentiation was confirmed with CD31-A lexa594, 
KDR-Alexa594 and vW F-FITC  staining. Specific staining for hepatocyte-like cells 
was performed using anti-album in-Cy3, an ti-C K 18-C y3 and an ti-H N F -F IT C  
antibodies. Astrocyte/neuronal differentiation was confirmed with staining for 
G LAST-FITC, G FAP-Cy3. Occasionally some differentiated cells also acquired 
expression of Tau/GABA and Tau/DOPA respectively. Magnifications: X200.
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Figure 25. Clonally derived SSEA-1pos cells have high differentiation capacities 
in vitro
FACS histograms showing levels of expression of specific antigens in S SEA -1pos 
clone-3 derived cells before and after in vitro differentiation into osteogenic 
(osteocalcin and BSP II), endothelial (extracellular CD31, vWF and extracellular Tie- 
2) hepatocyte (albumin and HNF) and astrocyte (GFAP, GLAST) lineages. The 
expression of these specific antigens was not detected before in vitro stimulation. All 
FACS plots shown: grey and white areas are the isotype control and specific 
antibody staining respectively. The numbers shown indicate the relative levels of 
expression for each antigen, calculated using the M.F.I (mean fluorescent intensity) 
values obtained from each specific staining over the values from their respective 
isotype controls.
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Although clone-3 cells were already able to uptake low-density-lipoprotein 
before stimulation, this functional feature was dramatically enhanced after 
cells had been incubated with VEGF (Figure 28b). Next, it was tested 
whether differentiated cells would form “vascular tubes” when plated on 
matrigel and also to respond to inflammatory cytokines. Indeed, endothelial- 
like cells were able to form tubular structures using the angiogenesis assay, 
and upregulate some adhesion molecules upon IL-1a exposure (Figure 28a, 
28c).
The addition of EGF/bFGF to the culture condition induces muMSCs 
to differentiate into both astrocyte and neuronal-like cells, thus It was chosen 
to focus the functional assays on a more astrocyte-orientated perspective 
(Duan et al., 1999; Haydon, 2001; Stanimirovic et a i , 1999). For astrocyte 
lineage, differentiated cells were able to uptake glutamate, specifically using 
Na+ channels (Figure 29a), respond to different neurotransmitters (Figure 
29c) and demonstrate important astrocyte-orientated metabolic activity, such 
as glutamine synthetase activity (Figure 29b) (Duan et al., 1999; Haydon, 
2001; Stanimirovic et al., 1999). In summary, these results indicate that 
clonally derived population has a high differentiation capacity with the 
acquisition of functional features in vitro.
5.4 - Clone-3 SSEA-1 pos-MSCs can incorporate into different 
tissues in vivo
So far, data from the literature on the contribution of MSCs into 
different tissue cell-types in vivo has been somewhat discouraging. Thus, in 
order to examine that SSEA-1pos cells have truly multipotential capacities in 
vivo, clone-3 cells were injected into non-irradiated NOD/SCID/P2™1 newborn 
mice and their distribution and contribution to different tissue cell-types was 
assessed. For this experiment newborn mice were used because their 
tissues are in a state of rapid growth, thus it might create a better 
environment for incoming stem cells to be incorporated and proliferate than
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Figure 26. Clone-3 SSEA-1pos cells acquired high levels of AP activity and 
calcium deposition upon osteogenic differentiation
Representative data from two independent experiments that were carried out with 
cells from 22 to 35 doublings. After 14 days in the presence of osteogenic induction 
medium, clonally derived cells acquired high levels of alkaline phophatase activity 
(a) and deposited high levels of calcium (b) (Dif. Bars). These functional features 
were not observed before induction (Undif. Bars). All quantitative results shown are 
mean ± SD from two independent experiments, each one performed in triplicate.
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Figure 27. Differentiation of clonally derived SSEA-1pos cells into hepatocyte- 
like cells with some functional features in vitro
Representative data from two independent experiments that were carried out with 
cells from 22 to 35 doublings. Hepatocyte-like cells derived from clone-3 cells were 
able to deposit glycogen (a; PAS assay; glycogen storage is seen as accumulation 
of magenta staining) and showed cytochrome P450 activity (b; PROD assay; activity 
is seen as red staining). The cytochrome P450 activity in the differentiated cells can 
be dramatically induced in the presence of Phenobarbital. None of these assays 
were positive using undifferentiated cells. Magnification: X200.
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Figure 28. Differentiation of clonally derived SSEA-1906 cells into functional 
endothelial-like cells in vitro
Representative data from two independent experiments that were carried out with 
cells from 22 to 35 doublings. Although undifferentiated cells w ere able to 
occasionally form tubular structures in the angiogenesis assay (a) and uptake some 
LDL (b, red staining), these functional features were drastically enhanced after the 
cells were exposed to V E G F for two weeks. Differentiated cells also acquired 
expression of Tie-2 (F ITC ), which co-localized with LDL staining. Moreover, 
differentiated cells were able to up-regulate MHC-I, VCAM-1, ICAM-1 and P-selectin 
after 6 h of IL-1a exposure (c). Magnifications: X 100 (a; angiogenesis assay and 
Undif. of Ac-LDL uptake), X200 (b, Dif. Ac-LDL uptake).
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Figure 29. Differentiation of clonally derived S S E A -I1* 8 cells into cells of 
neuroectoderm lineage with some functional astrocytic features in vitro. 
Representative data from two independent experiments that were carried out with 
cells from 22 to 35 doublings, (a) Approximately two-thirds of 3H-glutamate uptake 
was Na+-dependent (dark blue bar); Non-stimulated cells had a basal level of 3H- 
glutamate uptake (even in the presence of extracellular N a+; black bar), with values 
similar to those obtained with differentiated cells when Na+was not added to the 
culture (light blue bar), (b) Glutamine synthetase activity in differentiated cells. The 
activity was determined using the colorimetric assay as described in Materials and 
Methods. Again, this activity was minimal in undifferentiated cells (black bar) but 
present in differentiated cells (dark blue bar), (c) Astrocyte/neuronal-like cells were 
also able to respond to different neurotransmitters such as K+, glutamate and 
histamine. These responses were measured by intracellular calcium fluxes using 
flow cytometry. The fluorescence emission spectrum of lndo-1 shifts after binding to 
calcium; thus, the ratio obtained by dividing the signal collected on FL4 and FL5 
channels changed depending on the intracellular levels of free C a2+. Flow plots 
show the time course of C a2+ shifts (200 s) with the basal levels obtained before the 
addition of any substance (time of addition is indicated by the arrows), lonomycin 
was used as positive control. All quantitative results shown are mean ± SD from two 
independent experiments, each one performed in triplicate.
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the adult milieu. Since all the studies were based on MSCs derived from 
NOD/SCID bone marrow (including clone-3 cells) and were also aimed to 
use cells with the minimum of cell doublings and in vitro manipulation (e.g. 
transduction with a reporter gene), it created some limitation for the 
assessment of the in vivo engraftment. Therefore, only tissues where the 
expression of MHC-I (Major Histocompatibility Class-1; donor marker) was 
high were selected. Consequently, potential incorporation of donor-derived 
cells may have been missed in other tissues not mentioned here. 
Consequently, mainly different epithelium (kidney, liver, gut and lung) and 
haematopoietic organs (bone marrow and spleen) were screened for the 
presence of donor-derived cells.
Although distribution and levels of incorporation varied from mouse to 
mouse, in 2 out of 5 animals clone-3 cells incorporated into gut epithelial 
cells with proper morphology and expressing pan-CK (Figure 30). MHC-lpos 
cells expressing albumin in the liver of one mouse were also able to be 
detected. MHC-lpos/vWFpos endothelial-like cells were also detected in the 
liver (F igure 32). In addition, specific MHC-lpos cells were observed in the 
kidneys of 2 mice. These cells had renal tubular epithelial cell morphology 
and were seen in clusters. These donor-derived cells stained positively for 
lectins Ricinus communis (F igure 30). No lung epithelial cells were detected 
in any of the animals. At first glimpse of the data presented it appeared that 
these contribution events were rare but in reality they were actually 
substantial. Firstly, only 10 non-serial tissue-sections/organ were screened 
and presence of donor derived cells were found quite easily. Unlike in 
Chapter-3 using bulk cultures of MSC, where many more animals and tissue- 
sections/organ were screened, and very little incorporation of donor cells in 
the recipient’s tissues was found.
Due to the nature of the donor cell-type, there was a limitation in 
addressing whether the events observed were due to the controversial data 
on fusion with hematopoietic cells (Harris et al., 2004; Jang et al., 2004; 
Terada et al., 2002; Wang et al., 2003). Despite the limited data reported on 
the contribution of MSC to different cell-types in vivo, so far none seem to be 
due to fusion (Kogler et al., 2004; Pochampally et al., 2004; Sato et al., 
2005). Based on the fact that these same cells have high endodermal and
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endothelial capacities in vitro, this indicates that under favourable 
environment they could also differentiate in vivo into different tissues. 
Moreover, the events presented were always seen as clusters of cells and 
not single cells, therefore it is less likely that fusion had occurred in such a 
fashion. Although, it cannot exclude the possibility that expansion of fused 
cells had also occurred. It is possible that both mechanisms could have 
contributed to such events. Further isolation of SSEA-1pos cells from other 
strains of mice will be necessary in the future in order to address the 
mechanisms behind the events observed.
5.5 - Clone-3 SSEA-1 pos-MSCs can differentiate into 
haematopoietic cells in vivo
Clonally derived SSEA-1pos cells could also give rise to 
haematopoietic cells in all the recipient animals. These donor-derived 
haematopoietic cells were found in the spleen (data not shown) and in the 
bone marrow (F igure 31). Most MHC-l/CD45pos cells had myeloid markers 
(CD45pos/Gr-1pos) (F igure  31f), although low levels of CD45pos/CD19pos 
(F igure  31f), and Ter119pos (F igure  31e) could also be detected. 
Interestingly, multicolour flow-cytometry analysis revealed high frequency of 
donor-derived cells with CD45pos/KLS phenotype (F igure 31 h, 31 g) (0.6- 
3.5%). These data suggest that SSEA-1pos-MSCs are capable of 
differentiating into haematopoietic cells, potentially through an HSC stage. 
Clonally derived SSEA-1pos were obtained from NOD/SCID and thus these 
cells have a defect in B and T cell development. Consequently, the only 
lymphoid cells present could only be pre/pro-B cells. Immunocompetent 
derived SSEA-1pos cells are required to fully appreciate this conversion, 
especially to different lymphoid cell-types. Indeed, further detailed 
characterisation of the cellular/molecular events involved in this 
mesenchymal-haematopoietic “conversion” is of great the interest to the lab.
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Figure 30. Engraftm ent and incorporation o f S S E A -11,08 clone-3 derived MSCs  
into d ifferent tissues in vivo
Examples of frozen tissue sections of engrafted mice (NOD/SCID-(32nul1) 8 weeks 
after infusion of 2x105 clone-3 derived cells (NOD/SCID-derived; at 28 doublings). 
Similar type of tissues from N O D /SC ID  and N O D /S C  I D-|32nul1 were also used as 
positive and negative controls for M H C -I expression (red staining; A lexa594) 
respectively. Showings are examples (one or two from different engrafted animals) 
of areas where incorporation of donor derived cells (M HC-I positive staining; red) 
were observed. Each example is followed by its respective serial section that was 
stained with a tissue specific antibody. Sections of gut, kidney and liver were stained 
with, anti-pan-CK-FITC, lectin Ricinius communis-F ITC  and anti-albumin-FITC/anti- 
vW F-FITC, respectively. All sections were counterstained with DAPI. Magnifications. 
X200 (liver and kidney: with the exception of the last highlighted area at X1000) and 
X400 (gut). Insert table shows the engraftment levels which were determined by 
immunohistochemistry; estimation of chimerism from the five recipient animals used 
in this study was accessed by counting the number of M HC-I positive cells seen on 
10 non-serial sections screened for the presence of donor-derived cells.
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To further confirm that clonally derived cells were not committed to any 
haematopoietic cells before in vivo inoculation, cells were 
immunophenotyped for several surface antigens (F igure 32). Also, detailed 
cell cycle analysis was performed on clone-3 SSEA-1pos cells showing that 
the cells had normal DNA content (F igu re  33). This was done to 
demonstrate that the contribution events in different tissue cell-types seen 
were not due to potential participation of polyploid cells in being able to 
incorporate into different tissues, as recently described by others (Rubio et 
al., 2005).
5.6 - Discussion
In this chapter it is described that a single SSEA-1pos cell derived 
population could not only give rise to functional mesenchymal, endothelial, 
endoderm and neuroectoderm cell lineages in vitro, but also could 
incorporate into different epithelia and endothelium and differentiate into 
haematopoietic cells in vivo when injected into newborn recipients. This is 
the first demonstration of a single mesenchymal cell derived population, 
which can be prospectively isolated from early adherent cultures using a 
defined marker and have multipotent capacities both in vitro and vivo.
It is also shown that the clonally derived population expresses high 
levels of Oct-4, Rex-1 and Nanog. Although surprising, these findings were 
not entirely unexpected. Firstly, they have been expanded for more than 35- 
45 doublings in MAPC medium; secondly, preliminary immunophenotype 
results using bone marrow cells from Oct-4-eGFP mice revealed the 
existence of an Oct-4-eGFP expressing population with considerable eGFP 
expression; these Oct-4-eGFPpos cells were indeed Lin/CD45neg and SSEA- 
1pos (personal observations). These results strongly suggest that SSEA-1pos 
cells in the bone marrow express Oct-4 and therefore support the data that 
SSEA-1pos cells found in bulk cultures did not emerge from ex-vivo 
conditions. In light of all the data and observations made it suggests that the 
expression of Oct-4 in SSEA-1pos cells in the bone marrow is present but is 
somehow downregulated upon exposure to simple culture conditions
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Figure 31. In vivo haematopoietic reconstitution ability of SSEA-1pos clone-3 
derived-MSCs
Representative flow cytometry plots of bone marrow engraftment analysis from one 
of the recipient mice. The assessment of donor-derived cells was determined by the 
presence of M HC-I expressing cells, (a, b) N O D /S C ID -p 2 nuM and NOD/SCID  
BMMNCs were used as negative and positive controls respectively. BM M NCs from 
each recipient animal were stained with an appropriate isotype control (c) and M HC- 
I antibodies (d) to determ ine the percentage of donor-derived cells. Multicolour 
FACS analysis shows that most of donor-derived cells (M H C -lpos; gated area of d) 
were haematopoietic origin, composed mainly by C D 45pos cells (e). Most of donor- 
derived C D 45pos cells co-expressed the myeloid antigen Gr-1 (f) and conversely 
were also positive for lineage-committed antigens (h). However, some cells with 
H SC/HPC phenotype, KLS (c-Kitlow/pos/Lineagene9/Sca-1pos) were also found (g). (i) 
Level of bone marrow engraftm ent of the five mice used in this study were  
determined by FACS; the percentages of M H C -lpos cells represent the number of 
positive cells found over the total BM M NCs analysed, whereas the other values 
represent their respective percentage within the M H C-lpos cells.
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Figure 32 - Clone-3 SSEA-1pos cells were not committed to haematopoietic 
cells before transplantation
Clone-3 SSEA - 1 ^  cells did not express any specific haem atopoietic surface  
antigens, except for CD34 before in vivo transplantation. Grey and white areas are 
the isotype control and specific antibody staining respectively.
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(therefore not appropriate for its maintenance) to the point that this 
expression was not even detectable when the SSEA-1pos cells were isolated 
from bulk cultures. However, when SSEA-1pos cells were isolated early 
enough and placed in a more appropriate culture medium (such as for 
MAPC), the expression of such embryonic transcription factors could be 
“rescued” and re-induced in these cells. Even though the exact function 
these transcription factors might have in the SSEA-1 pos-MSCs is not clear, 
the latest observations indicate they are lost when culture conditions are 
changed or the cells are forced to differentiate (personal observations). Thus, 
these transcription factors might have some function in the maintenance of 
the self-renewal and/or multipotency features in these cells, akin to ES cells 
(Chambers et al., 2003; Niwa etal., 2000). Evaluation of the gene expression 
profile of SSEA-1 pos-MCSs might uncover important key pathways, which 
regulate their in vitro self-renewal and unique “plastic” properties.
The findings described here will open new questions concerning the 
hierarchical organisation of MSCs, the role of SSEA-1pos-MCSs in the 
maintenance of tissue homeostasis and especially in the developmental 
origin and relationship of these cells with other cell-types, in particular with 
the haematopoietic cells. In fact, as demonstrated here, a clonally derived 
SSEA-1pos cell could contribute to haematopoietic reconstitution. 
Accumulating evidence suggests that a common precursor of mesenchymal 
and haematopoietic lineages might exist both in mice and humans (Dominici 
et al., 2004; Jiang et al., 2002; Kogler et al., 2004). This hypothesis could 
challenge current views on the developmental origin of haematopoietic stem 
cells. With the use of SSEA-1, and possibly Oct-4, it may be possible to trace 
the developmental origin of this primitive mesenchymal cell-type.
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Figure 33. Clonally derived population is not aneuploid
Cell cycle analysis of clone-3 population at 45 doublings showing normal DNA  
content, without a detectable polyploid peak (highlighted oval area). Peripheral 
blood (PB) C D 45/C D 19pos cells (from C57BL/6J) were used as reference of normal 
DNA content (area highlighted by the black box) and to set the G0/G1 peak and a 
stroma cell line M 210B4 as an example of presence of polyploid peak.
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Conclusion
This project was initiated merely by curiosity, no plan or targets were 
initially drawn up for this particular study. Most of the initial studies on 
muMSCs aimed to address simple questions, such as characterisation of 
basic isolation/expansion methods, phenotype and differentiation capacities 
of these cells, since these points were not properly addressed for muMSCs. 
During the process of defining culture conditions for isolation and ex vivo 
expansion of adult murine MSCs, a new cell-type was found. Under a 
conventional isolation/culture system a minor sub-population of muMSCs 
was identified with MAPCs features (based on the expression of SSEA-1 
antigen). MAPCs were characterised by Catherine Verfaillie’s group and 
shown to have the capacity to differentiate into different cell-types of the 
three-germline layers, both in vitro and in vivo, thus resembling embryonic 
stem cells. The presented data strongly suggest that this new subpopulation 
is the founder of the MSC compartment; as they give rise to the SSEA-1neg 
cells, with limited differentiation potential, and also they are required to 
initiate bulk MSC cultures.
These SSEA-1 pos-MSCs exhibit some common features in common 
with MAPCs: they can differentiate into different cell-types of the three- 
germline layers in vitro, incorporate into different epithelia and endothelium 
and differentiate into haematopoietic cells in vivo. Furthermore, they also 
express specific embryonic transcription factors such as Oct-3/4, Rex-1 and 
Nanog.
Most importantly, these cells can be found not only after in vitro 
culture but also directly from mouse bone marrow, therefore proving their 
true existence in vivo. Although SSEA-1 pos-MSCs described in this study 
share some features of ES cells but they differ from them by expressing, for 
example, MHC-I and AP, and having different cell expansion requirements 
(e.g. confluency). Moreover, it still has to be demonstrated whether these 
cells can produce chimeras after blastocyst injections. As such, at this point, 
the results shown are not sufficient to support that these cells are reminiscent
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of ES cells in post-natal life. Further experiments are required to address this 
very important and interesting issue. Hopefully, using the recently acquired 
Oct-4-GFP mice will give a better understanding on the biology and 
developmental origin of these cells.
MSCs can indeed incorporate into different tissue-types in vivo and 
therefore the in vitro “plastic” features described by many researchers and 
also reported here seem to be shared in vivo. However, it is important to 
emphasise the weakness of this study concerning the interpretation of the in 
vivo results shown. As mentioned earlier, this study was not designed 
properly to address and pursue in vivo studies. Basically, the lack of 
appropriate mouse strains (e.g. the cre-lox system) and injury models for 
targeting specific tissues created a tremendous difficulty to detect and 
address the mechanisms behind these incorporation events. SSEA-pos cells 
derived from more suitable mouse strains are required to better understand 
whether these events were due to differentiation or fusion with resident cells. 
Also, by focusing (direct inoculation of the cells or use of an injury model or 
both) on one particular tissue of interest, rather than screening randomly 
multiple tissues would dramatically ease studies of this kind. The lab is 
especially enthusiastic on the mesenchymal-haematopoietic conversion, and 
it will be very interesting to know whether these SSEA-1pos cells could 
convert into fully functional long-term haematopoietic stem cells. Also, to 
further support the notion that the newly identified cell-type behaves like ES 
cells, it will be important to investigate if this conversion follows a similar 
molecular/cellular pattern as the ES cell.
At last, but not least, the fundamental question, whether these SSEA- 
1pos cells can fit into the definition of a stem cell. In vivo a stem cell is 
capable of regeneration or maintenance of a tissue compartment at a single 
cell level, thus it can be transplanted, re-isolated, and serially transplanted. 
Using this stringent criterion, which is applied for haematopoietic stem cells, 
SSEA-1pos cells still do not fit into the definition, especially concerning the 
serial transplantability point of view. Although SSEA-1pos cells have self­
renewal properties in vitro under the MAPC culture system, it was not tested
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here if these cells can “home” and repopulate adult bone marrow and 
therefore be able to be re-isolated and to engraft into secondary recipients. 
As shown in Chapter-3, when MSCs were infused intravenously into adult 
recipient mice, no donor-derived cells were found in the recipient’s marrows. 
Although in these experiments bulk MSCs cultures were used, those cultures 
contained some SSEA-1pos cells (< 1%). The “homing” properties of MSCs in 
general might have been lost upon culture and therefore it would be 
challenging to conduct such studies. Intra-bone administration of SSEA-1pos 
cells may help to overcome this problem. Secondly, it is not known what role 
these cells have in the maintenance of the homeostasis and repair of the 
bone marrow. As shown here, these cells gradually disappear during aging 
and this finding suggests that they might not play a great homeostatic role 
during the adult lifetime of the animal. It is tempting to speculate that direct 
progenitors of these cells (e.g. osteoprogenitors, adipocyte progenitors, etc) 
might actually participate most (if not to all) the homeostatic and repair 
functions in the marrow. These experiments are absolutely essential in order 
to prove that these SSEA-1pos cells are stem cells by definition.
Finally, it is important to emphasise that the nomenclature applied for 
describing bulk cultures of bone marrow adherent cells (even after the 
haematopoietic depletion) as MSC is not adequate. As postulated by many 
researchers and also shown here, what is obtained from the adherent 
isolation method is a mixture of fibroblastic cells, with most of them not 
having either stem or progenitor features. Only for the “sake” of a consensual 
scientific understanding, this commonly used designation was opted for. 
Perhaps bone marrow mesenchymal cells, BMMCs, might be more 
appropriate for what has been described as MSC or MPC. However, it is 
hoped that with further investigation in the near future that the SSEA-1pos cell 
can be finally named as the true MSC.
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Appendix I - Solutions
Hst Buffer
Hank's balanced salt solution (CRUK, central cell services) 
20 Mmol/ml of HEPES (Gibco)
1 mg/ml of Glucose (Sigma)
10% FBS (Gibco)
AP Buffer, pH7.4
15 mM Tris-HCI (BDH)
1 mM ZnCI2 (BDH)
1 mM MgCI2 (BDH)
1 % TX (Sigma)
Krebs Buffer, pH 7.2
4.8 mM KCI (BDH)
1.2 mM KH2P04 (BDH)
1.3 mM CaCI2 (BDH)
1.2 mM MgS04(BDH)
25 mM HEPES
6 mM Glucose (Sigma)
140 mM NaCI (BDH) or Choline-CI (Sigma)
GS Buffer, pH 7.2
0.15 M KCI
2 mM DTT (Sigma)
1 mM EDTA (Gibco)
GS Solution, pH 7.2
0.1 M imidazole-HCI (Sigma)
50 mM, L-glutamine (Gibco)
0.4 mM MnCI2 (BDH)
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62.5 mM hydroxylamine (Sigma)
10 mM Na2HAsC>4 (Sigma)
Ferric Chloride Reagent
0.37 M FeCh (Sigma)
0.67 M HCI
0.2 M TCA (Sigma)
Resolving gel (10% gel), 25 ml
8.3 ml of 30% acrylamide/bisacrylamide (29:1 mix) (National Diagnostics, 
Atlanta, US)
3.15 ml of 8x Resolving gel buffer (National Diagnostics)
13.3 ml of water
10 Ml of TEMED (Sigma)
250 pi of 10% ammonium persulfate (Sigma)
Stacking gel, 8 ml
1.3 ml of 30% acrylamide/bisacrylamide (29:1 mix)
2 ml of 4x Stacking gel buffer (National Diagnostics)
4.7 ml of water
8 Ml of TEMED
80 Ml of 10% ammonium persulfate
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Appendix II - Primers
Genomic PCR Primers
-eGFP
F: 5’-CAACAGCC ACAACGT CT AT AT CAT G-3’
R: 5-GAAGTTCTAGGCGGTGTTGTA-3’
-muGAPDH
F: 5’-CGGAGTCAACGGATTTGGTCGTAT-3’
R: 5’-AGCCTT CTCCAT GGT GGT GAAGAC-3’
RT-PCR and Real-time RT-PCR Primers
(Unless is stated all the reactions were performed at 60 °C as annealing 
temperature for 40 cycles)
-Albumin
F: 5'-GCATGAAGTTGCCAGAAGACATCC-3'
R: 5'-T CT GC AGTTT GCT GG AG AT AGT CG-3'
-fi-actin (55 °C; 30 cycles)
R: 5’-TTCCTTCTTGGGTATGGAAT-3’
F: 5’-GAGCAATGATCTTGATCTTC-3’
-ft-actin (Real-Time)
F: 5’-ACCAACTGGGACGATATGGAGAAGA-3’
R: 5’-TACGACCAGAGGCATACAGGGACAA-3’
-BSP II
F: 5'-TTTCCACACTCTCGGGTGTAA-3'
R: 5'-CCGCCAGCT CGTTTT CAT C-3'
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-Myogenin
F: 5-CCCAACCCAGGAG ATCATTT -3'
R: 5'-GTCTGGGAAGGCAACAGACA -3*
-Nanog
F: 5’-AGGGT CT GCT ACT GAG AT GCT CT G-3’ 
R: 5’-CAACCACTGGTTTTTCTGCCACCG-3’
-Rex-1 (55 °C)
F: 5’-CGTGTAACATACACCATCCG-3’
R: 5’-GAAATCCTCTTCCAGAATGG-3’
-Rex-1 (Real-Time)
F: 5’-AAGCGTTTCTCCCTGGATTTC-3’
R: 5-TTTGCGTGGGTTAGGATGTG-3’
-Tie-2
F: 5'- TCCCTCCTCAACCAGAAAACA-3'
R: 5'- T CT C AGC AAAAAT AT CC AC AT GGT-3'
-vWF
F: 5'-CCGGAAGCGACCCTCAGA-3'
R: 5'-CGGT CAATTTT GCCAAAG AT CT-3'
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Appendix HI -Antibodies
Primary Antibodies
Anti- Form at C lone/D esignationl A pplication/D ilution I Source
ci407 integrin Purified D A K T 32 F C (1 :5 0 )  I Pharm inqen
Albumin Purified H A S -1 1 FC  (1:10); IF (1 :400); IH (1 :200); W B  (1 :4 0 0 ) S iqm a
a -S M A Purified A 2 5 4 7 IH (1 :1 00 ) S iqm a
07 integrin F IT C F IB 50 4 FC  (1 :5 0) Pharm inqen
0-Actin Purified A C -1 5 W B  (1 :4 00 ) S iqm a
BSPII Purified M A P F C  (1 :10): IF (1 :200): W B  (1 :4 0 0 ) C osm oB io
C 1 cjR d/AA4.1 F IT C AA4.1 F C  (1 :5 0 ) Pharm inqen
C D 2 P E R M 2 -5 F C  (1 :5 0 ) Pharm inqen
C D 3 e C v-C h ro m e 1 4 5 -2 C 1 1 FC  (1 :5 0 ) Pharm inqen
C D 4 P E G K 1 .5 FC  (1 :5 0 ) Pharm inqen
C D 5 P E 5 3 -7 .3 FC  (1 :5 0) Pharm inqen
C D 8a P E 5 3 -6 .7 FC  (1 :5 0 ) Pharm inqen
C D 9 Biotinvlated K M C 8 FC  (1 :1 0 0 ) Pharm inqen
C D 11a Purified H 6 8 F C  (1 :5 0 ) C R U K
C D 11b Purified M 1 /7 0 IH (1 :2 5 ) Pharm inqen
C D 1 1 b P E M 1 /7 0 F C  (1 :5 0 ) Pharm inqen
C D 11b Biotinvlated M 1 /7 0 F C  (1 :1 00 ) Pharm inqen
C D 11c F IT C H L3 FC  (1 :5 0 ) Pharm inqen
C D 14 P E rm C 5-3 F C  (1 :5 0) Pharm inqen
C D 1 9 Biotinvlated 1D 3 FC  (1 :5 0) Pharm inqen
C D 25 PE 3C 7 FC  (1 :5 0) Pharm inqen
C D 29 Purified 9 E G 7 FC  (1 :5 0) Pharm inqen
CD31 Purified M E C 1 3 .3 F C  (1 :30) Pharm inqen
CD31 Biotinylated 390 F C  (1 :1 00 ) Pharm inqen
CD31 F IT C 390 F C  (1 :50) Pharm inqen
C D 34 PE R A M  34 F C  (1 :5 0 ) Pharm inqen
C D 34 F IT C R A M  34 FC  (1 :5 0 ) Pharm inqen
C D 43 P E S7 F C  (1 :5 0) Pharm inqen
C D 44 A P C IM 7 F C  (1 :5 0) P harm inqen
C D 45 Purified 3 0 -F 1 1 F C  (1 :3 0) Pharm inqen
C D 4 5 Biotinvlated 30-F11 F C  (1 :1 50 ) P harm inqen
C D 4 5 F IT C 30-F11 F C  (1 :5 0) Pharm inqen
C D 4 5 P E -C v7 30-F11 F C  (1 :7 5) Pharm inqen
C D 45 C v-C h ro m e 30-F11 F C  (1 :7 5) P harm inqen
C D 4 5 R /B 2 2 0 PE R A 3-6B 2 F C  (1 :5 0) Pharm inqen
C D 4 9 e PE 5 H 10-27 F C  (1 :5 0 ) Pharm inqen
C D 49f F IT C G 0 H 3 F C  (1 :5 0 ) Pharm inqen
C D 62E Purified 10E 9 .6 F C  (1 :5 0 ) Pharm inqen
C D 62L Purified M e l-14 F C  (1 :50) Pharm inqen
C D 62P Purified R B 40 .34 F C  (1 :50) Pharm inqen
C D 73 PE T Y /2 3 F C  (1 :5 0 ) Pharm inqen
C D 90 F IT C H IS51 F C  (1 :50) P harm inqen
C D 1 0 3 Purified M 2 9 0 F C  (1 :5 0 ) Pharm inqen
C D 105 Purified M j7 /18 F C  (1:25): IH (1 :10) Pharm inqen
C D 106 F IT C M /K -2 F C  (1 :50) Chem icon
C D 1 1 7 A P C 2B 8 FC  (1 :50) Pharm inqen
C D 127 PE S B /1 9 9 F C  (1 :50) Pharm inqen
C D 1 3 5 PE A 2 F 10.1 F C  (1 :5 0) Pharm ingen
C K 18 Purified CY-90 IF (1 :4 00 ) S iqm a
C X C R 4 F IT C 2 B 1 1 /C X C R 4 F C  (1 :5 0 ) Pharm inqen
D D C Purified D D C  109 IF (1 :4 00 ) S iqm a
Desm in Purified 33 F C  (1:15): IF (1:50); IH  (1:80): W B  (1 :2 0 0 ) D ako
DvstroDhin Purified H -3 0 0 F C  (1:10): IF (1 :400): W B  (1 :4 00 ) S .C ru z
FTM Purified M Y -3 2 IF (1 :4 00 ) Siqm a
G ABA Purified A 2 0 5 2 IF (1 :4 00) Sigm a
G FA P Purified H -5 0 F C  (1 :10); IF (1 :400): W B  (1 :4 00 ) S .C ruz
G F P Purified FL F C  (1:10): IH  (1 :4 00) S anta C ruz
G F P Purified 3 E 1 . F C  (1:10); IH (1 :4 00) C R U K
G LA S T Purified a b 4 1 6 F C  (1:10): IF (1:400): W B  (1 :4 0 0 ) A beam
GR-1 PE R B 6 -8 C 5 F C  (1 :50) P harm inqen
H-2D" Purified H B 27 IH (1 :2 00 ) C R U K
H-2K° Purified K 9 -18 IH (1 :2 0 0 ) C R U K
H-2K° F IT C S F 1-1 .1 FC  (1 :50) Pharm inqen
HNF-1 Purified H -2 0 5 FC  (1:10); IF (1 :200); W B  (1 :4 00 ) S .C ru z
l-A PE A M S -32 .1 FC  (1 :50) Pharm inqen
lcam-1 Biotinvlated 3E 7. FC  (1 :5 0 ) Pharm inqen
lcam -2 F IT C 3C 4 FC  (1 :5 0 ) Pharm inqen
KD R/FLK -1 Purified 89B 3A 5 FC  (1 :5 00 ) Chem icon
Lectin L. esculentum Biotinvlated L0651 IH (1 :1 00 ) Siqm a
Lectin L. tetraqonolobous Biotinvlated B 1 325 IH (1 :1 00) V ector Laboratories
Lectin R. communis Biotinvlated B 1 085 IH (1 :1 00 ) Vector Laboratories
M adC A M -1 Biotinvlated M EC  A /89 FC  (1 :1 00 ) Pharm inqen
N anoa Purified ? IF (1 :4 00) C osm oBio
NeuN Purified M A B 377 IF (1 :4 00 ) Chem icon
NK1.1 PE P K 136 FC (1 :5 0 ) Pharm inqen
O ct-4 Purified H -134 IF (1 :1 00) S .C ruz
O steocalcin Purified M -1 5 FC  (1:10); IF (1:400); W B  (1 :4 00) Santa C ruz
o an-C K Purified H -2 4 0 IH (1 :2 00) S .C ru z
Pro-Sulfactan Protein C Purified A B 3428 IH (1 :1 00) Chem icon
Rex-1 (Z F P 4 2) Purified A P 2051 b IF (1 :1 00) A bqent
Sca-1 Biotinvlated E 1 3 -1 6 1 .7 FC  (1 :1 00) Pharm inqen
Sca-1 F IT C E 1 3 -1 61 .7 FC  (1 :1 00) Pharm inqen
Sca-1 PE E 1 3 -1 6 1 .7 FC  (1 :1 00) Pharm inqen
SSEA -1 Ascites 480 F C  (1 uq /10” cells) D S H B
SSEA -1 Purified 480 FC  (1:15); IF (1 :100): IH (1 :50) S anta C ruz
Tau Purified H -150 IF (1 :4 00) S .C ruz
T E R -1 1 9 A P C T E R -1 1 9 FC  (1 :1 00 ) eB ioscience
T E R -1 1 9 Purified T E R -1 1 9 IH (1 :25) Pharm inqen
T E R -1 1 9 PE T E R -1 1 9 F C  (1 :1 00 ) P harm inqen
T ie -2 Purified H -176 FC  (1:10); IF (1 :4 00) S anta  C ruz
Trk (N G F R ) Purified C -1 4 F C  (1:25): IH (1:10) S .C ru z
vW F Purified H-300 FC  (1:10); IF (1 :400); IH (1:200): W B  (1 :4 0 0 ) S anta C ruz
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Secondary Antibodies/Reagents
Anti- Format Application/Dilution Source
Goat IgGs FITC FC (1:50); IF (1:400) Dako
Goat laGs AlexaFluor647 FC (1:50) Molecular Probes
Goat IgGs Cv3 IF (1:400) Jackson Immuno.
Goat IgGs P O D W B  (1:800) Santa Cruz
Mouse lgG1 AP C FC (1:50) Pharmingen
Mouse lgG1 FITC FC (1:50) Pharmingen
Mouse lgG2a FITC FC (1:50) Pharmingen
Mouse lgG2b FITC FC  (1:50) Pharmingen
Mouse lgG2b PE FC  (1:50) Biocarta
Mouse IgGs AlexaFluor594 IF (1:400) Molecular Probes
Mouse IgGs ALK IH (1:800) Vector
Mouse IgGs Biotinvlated FC  (1:100) DAKO
Mouse IgGs FITC FC (1:50); IF (1:400) Sigma
Mouse IgGs FITC FC (1:50); IF (1:400) Abeam
Mouse IgGs PO D IH (1:800): W B (1 :1000) Sigma
Mouse IgGs AlexaFluor488 IF (1:400) Molecular Probes
Mouse IgM A PC FC (1:50) Pharmingen
Mouse IgM Biotinvlated FC  (1:25): IH (1:100) Sigma
Mouse IgM FITC FC (1:25): IH (1:100) Biocarta
Mouse IgM PE FC (1:50) Biocarta
Mouse IgM TexasR ed IF (1:100) S.Cruz
Rabbit IgGs AlexaFluor488 IF (1:400): IH (1:400) Molecular Probes
Rabbit IgGs AlexaFluor647 IF (1:400): IH (1:400) Molecular Probes
Rabbit IgGs Cv3 IF (1:400) Jackson Immuno.
Rabbit IgGs PE FC (1:100) Southern Biot.
Rabbit IgGs PO D IH (1:800): W B  (1 :1000) Sigma
Rabbit IgGs TR IT C IF (1:400) Sigma
Rat loG2a FITC FC (1:100) Serotec
Rat lgG2b FITC FC (1:100) Serotec
Rat IgGs AlexaFluor488 IF (1:400): IH (1:400) M olecular Probes
Rat IgGs AlexaFluor594 IF (1:400): IH (1:400) Molecular Probes
Rat IgGs FITC FC (1:100) Serotec
Streptavidin APC FC (1:100) Pharmingen
Streptavidin Cv-Chrom e FC (1:100) Pharmingen
Streptavidin FITC FC (1:100) Pharmingen
Streptavidin PE FC (1:100) Pharmingen
Streptavidin PerCP FC (1:100) Pharmingen
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